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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Fetma är kopplat till störningar i kroppens ämnesomsättning och kan ge upphov till 
sjukdomar som typ 2 diabetes. Men det är inte bara mängden fett som avgör om man blir sjuk 
av sin fetma, utan även vilka egenskaper fettväven har. Den effektivaste behandlingen av 
fetma är fetmakirurgi, till exempel så kallad gastrisk bypass. I denna avhandling studeras 
kopplingen mellan olika egenskaper hos fettväven och störningar i ämnesomsättningen, samt 
hur detta förändras efter viktnedgång.   
Studie I. Vid samma fettmängd i kroppen kan fettväven bestå av många små fettceller eller få 
men stora fettceller. Det senare har visat sig förknippat med försämrad känslighet för 
kroppens insulin, vilket är ett förstadium till typ 2 diabetes. I denna studie undersöktes om 
fettcellernas storlek i förhållande till fettmängden i kroppen kan förutsäga förbättrad 
känslighet för kroppens insulin efter viktnedgång (genom kostförändring eller gastrisk 
bypass). Studien visade att de med störst fettceller i förhållande till fettmängd förbättrade sin 
insulinkänslighet mest efter viktnedgång, vilket inte kunde förutsägas genom enklare mått 
som body mass index (BMI) eller förhållandet mellan midje- och höftomfång (midje-höft 
kvot).  
Studie II. I denna studie jämfördes ämnesomsättning och fettväv hos patienter som gått ned i 
vikt genom gastrisk bypass med patienter som inte gått ned i vikt men hade samma BMI, kön, 
ålder och fettmängd. Studien visade att patienter som gått ned i vikt har bättre 
insulinkänslighet och blodfetter än patienter med samma BMI som inte gått ned i vikt. 
Dessutom hade försökspersonerna som gått ned i vikt en bättre fettväv med fler men mindre 
fettceller, mindre mängd bukfett och en mer gynnsam utsöndring av proteiner ur fettväven. 
Studie III. Fettväven utsöndrar många olika proteiner som kan påverka kroppen och ibland 
störa ämnesomsättningen. I studie III undersöktes om ett visst protein, som kallas ”CCL18”, 
utsöndras från fettväven och om det är förknippat med störd ämnesomsättning. Studien 
visade att CCL18 utsöndras från fettväven och att denna utsöndring och nivåerna i blodet var 
kopplat till störningar i ämnesomsättningen. Några tydliga effekter av CCL18 på olika 
celltyper i fettväven kunde inte påvisas.    
Studie IV. Här undersöktes om fettmängd och fettfördelning i kroppen kan förutsäga 
viktnedgång eller förbättrad ämnesomsättning efter gastrisk bypass. Kroppens fettmängd och 
fettfördelning mättes med en röntgenundersökning, så kallad DXA, innan operationen och 
uppskattades även med enklare mått som BMI och midje-höft kvot. Efter operationen 
förbättrades alla värden och fettet omfördelades i kroppen. Fettfördelningen mellan midja och 
höfter innan operationen kunde förutsäga hur mycket känsligheten för insulin förbättrades 
efter viktnedgång, och andelen kroppsfett kunde förutsäga hur mycket man gick ned i vikt. 
De enklare måtten kunde förutsäga utfallen ungefär lika bra som röntgenundersökningen, och 
värdet av röntgenundersökningen innan operation verkar därför vara begränsat.    
 
  
  
ABSTRACT 
Adipose tissue is closely linked to metabolic disturbances in obesity. Bariatric surgery such 
as roux-en-Y gastric bypass (RYGB) remains the most effective treatment of obesity and 
obesity-related disease. More factors than fat mass per se determine the metabolic 
complications of obesity, including alterations in fat cell size, body fat distribution, adipose 
protein release, inflammation and lipolysis. The aim of this thesis was to further characterize 
the relationship between adipose tissue characteristics and metabolic parameters before and 
after weight loss, and to investigate if adipose phenotype can predict metabolic improvement 
after weight loss.  
Study I. At any given fat mass, adipose tissue may constitute of many small fat cells 
(hyperplasia) or few but large fat cells (hypertrophy). This latter morphology is associated 
with worse metabolic profile. Study I examined if adipose morphology, i.e. hyperplasia or 
hypertrophy, could predict improved insulin sensitivity after weight loss. Abdominal 
subcutaneous adipose biopsies were performed before weight loss by diet or RYGB. Body fat 
mass was measured by dual-energy x-ray absorptiometry (DXA) or bioimpedance and insulin 
sensitivity assessed by homeostasis model assessment of insulin resistance (HOMA-IR). 
Results showed a higher improvement in HOMA-IR in patients with hypertrophy.  
Study II. The degree of improvement in metabolic profile and adipose tissue phenotype after 
weight loss is in relation to weight stable controls is not fully understood. In this study, 
women that had undergone RYGB were compared with a weight stable matched control 
group. Subjects that had undergone RYGB had lower HOMA-IR, better lipid profile and 
higher adiponectin levels and their adipose tissue was characterized by smaller fat cells, less 
visceral fat and lower secretion of tumor necrosis factor α (TNF-α) than controls.  
Study III. Herein, the CC chemokine ligand 18 (CCL18) was examined in adipose tissue. 
CCL18 was found to be released from adipose tissue in a time dependent manner. M2 
macrophages were the primary source of CCL18. Serum- and adipose secreted levels of 
CCL18 correlated with metabolic risk factors in women. We could not demonstrate effects of 
CCL18 on adipocyte expression of inflammatory or extracellular matrix proteins in vitro. 
Study IV. The aim of this study was to investigate if body fat mass distribution measured by 
DXA or simple anthropometric measures could predict improved metabolic profile or weight 
loss after RYGB. Android/gynoid fat mass ratio and waist-to hip ratio could predict improved 
HOMA-IR, and BMI and body fat percentage could predict weight loss. DXA measures and 
simple anthropometric measures performed equally well, indicating a limited value for DXA 
to predict metabolic outcome after RYGB.         
Conclusions: Adipose tissue morphology and body fat distribution can predict improved 
insulin sensitivity following weight loss. Metabolic and adipose phenotype improves beyond 
the control state after RYGB. CCL18 is released from M2 macrophages in adipose tissue, and 
adipose released and circulating levels correlate with metabolic risk markers in women.     
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1 BACKGROUND 
1.1 OBESITY  
1.1.1 Epidemiology 
Obesity is a growing health concern associated with extensive comorbidity and mortality
1
. 
The World Health Organization (WHO)
2
 defines overweight as a body mass index (BMI) ≥ 
25 kg/m
2 
and obesity as (BMI) ≥ 30 kg/m2. Since 1975, the world-wide prevalence of obesity 
has almost tripled. In 2016, 39 % of the adult population of the world had overweight, 
whereof 13 % had obesity
2
. The corresponding prevalence in the Swedish adult population 
was 51 % and 15 % respectively in 2016
3
.  
1.1.2 Metabolic syndrome 
Obesity is linked to development of metabolic complications such as type 2 diabetes mellitus 
(T2D), hypertension and dyslipidemia, which together with visceral obesity are clustered into 
the metabolic syndrome. The latter is associated with a marked increase in cardiovascular 
disease
4-6
 and can be defined in several ways based on different clinical parameters and cut-
off values. The most commonly used definitions are defined by WHO (1999)
7
, the Adult 
Treatment Panel III (ATP III) in 2002
4
 and the International Diabetes Federation (IDF) 2006
6
 
(Table 1). For some values, such as waist circumference and high-density lipoprotein (HDL) 
cholesterol, cut-off values differ between men and women. WHO included microalbuminuria 
as a criterion, while the IDF uses ethnic specific cut-off values for waist circumference. The 
European Group for the Study of Insulin Resistance (EGIR) suggested that insulin resistance 
or hyperinsulinemia (defined as the highest quartile in a non-diabetic population) should be a 
mandatory criterion
8
. In an attempt to unify the different criteria, a harmonizing definition
9
 
was proposed in 2009 after a joint meeting. Although the metabolic syndrome is well 
recognized and frequently used in clinical and research settings, it has been questioned 
whether the clustering of the individual risk factors is meaningful
10
.  
1.1.3 Treatment of obesity 
Identification of obesity complications including metabolic disturbances is important to 
identify patients that would benefit the most from weight loss, and to select proper treatment 
after adequate risk-benefit analyses in patients with obesity
11
. Treatment strategies in obesity 
include lifestyle interventions, medical treatment and bariatric surgery (surgery for weight 
loss). Five percent weight loss is usually considered clinically meaningful and associated with 
improved metabolic risk factors, although glucose metabolism may improve even after less 
weight loss and further improvements are expected after more pronounced weight loss
12
.    
Bariatric surgery is by far the most effective treatment, both in terms of weight reduction and 
metabolic improvement, as shown in comparative studies with conventional medical 
therapy
13-15
.  
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Table 1. Definitions of the metabolic syndrome by the World Health Organization (WHO), Adult 
Treatment Panel III (ATP III), International Diabetes Federation (IDF) and the joint Harmonizing 
definition  
 Abdominal 
obesity  
Blood lipids Blood 
pressure 
Blood 
glucose 
Additional 
criteria 
WHO
7 
Impaired 
glucose 
regulation plus 
two other 
criteria 
WHR 
 >0.90 (men); 
>0.85 
(women) 
Triglycerides 
≥1.7 mM 
and/or 
HDL cholesterol 
<0.9mM (men) 
<1.0 mM 
(women) 
≥140/90 
mmHg 
Impaired 
glucose 
tolerance, 
insulin 
resistance or 
type 2 
diabetes
a 
Microalbuminuria 
(urinary albumin 
excretion rate ≥20 
µg/min or 
albumin:creatinine 
ratio ≥ 30 mg/g 
ATP III
4 
3 or more 
criteria 
>102 cm 
(men)
b
 
>88 cm 
(women) 
 
Triglycerides 
≥1.7mM 
 
HDL cholesterol 
<1.0mM (men) 
<1.3 mM 
(women) 
≥130/85 
mmHg 
Fasting 
glucose ≥6.1 
mM 
 
IDF
6 
Abdominal 
obesity plus 
two additional 
criteria 
Ethnic 
specific: 
≥85-94 cm 
(men) 
≥80-90 cm 
(women) 
Triglycerides 
≥1.7mM 
 
HDL cholesterol 
<1.0 mM (men) 
<1.3mM 
(women) 
Systolic:  
≥130 
mmHg 
or 
Diastolic: 
≥ 85 
mmHg 
Fasting 
glucose ≥ 
5.6 mM  
or 
previously 
diagnosed 
type 2 
diabetes 
 
Harmonizing 
criteria
9 
Three of five 
criteria 
Ethnic 
specific: 
≥85-102 cm 
(men) 
≥80-90 cm 
(women) 
Triglycerides 
≥1.7 mM c 
 
HDL cholesterol 
<1.0 mM (men) 
 <1.3 mM 
(women) 
Systolic 
≥130 
and/or 
Diastolic 
≥85  
mm Hg
c 
Fasting 
glucose  
≥ 5.6 mMc 
 
a
 As defined by WHO. 
b “Some male persons can develop multiple metabolic risk factors when the 
waist circumference is only marginally increased, e.g. 94–102 cm”4. c Or corresponding drug treatment 
as alternative criterion. ATP III, Adult treatment panel III; HDL, high-density lipoprotein; IDF, 
International diabetes federation; WHO, World health organization; WHR, waist-to-hip ratio.  
1.1.3.1 Lifestyle interventions  
Lifestyle interventions with focus on increased physical activity, diet changes and weight loss 
induce an average 5-10 % decrease in body weight and in the frame of more intense programs 
also some metabolic improvement
16, 17
. Interventions with hypocaloric diets have been shown 
to induce more pronounced weight loss than exercise training
18, 19
, and a combination of diet 
and exercise is probably most effective
17
. There is no clear evidence demonstrating superior 
effects of any specific low-calorie diet, although Mediterranean diet may have more 
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beneficial effects including decreased risk of cardiovascular disease and very low-calorie diet 
may induce faster weight loss
20
. However, most patients regain body weight and sustained 
pronounced weight loss is difficult to achieve by lifestyle changes alone
17, 18
.  
1.1.3.2 Anti-obesity drugs 
Anti-obesity drugs have been reported to induce an average weight loss of 3-11.5 % 
depending on drug and dose, but have yet not been shown to reduce cardiovascular morbidity 
or mortality in patients with obesity without diabetes
21, 22
. The development of anti-obesity 
drugs has been limited by severe adverse effects for several substances as reviewed
23, 24
. The 
central nervous stimulant amphetamine was introduced for weight reduction during the 
1930s, but withdrawn after a couple of decades due to adverse effects including 
cardiovascular concerns and substance abuse. More recently, the norepinephrine and 
serotonin reuptake inhibitor sibutramin was withdrawn due to cardiovascular adverse effects, 
and the cannabinoid receptor antagonist rimonabant was withdrawn because of psychiatric 
adverse effects including depression and suicide
23, 24
. The gastrointestinal lipase inhibitor 
orlistat and the gut hormone (i.e. incretin) glucagon-like peptide 1 (GLP-1) analogues are 
some of the few currently accessible alternatives for weight loss
21, 23
. In the USA, the two 
combination drugs phentermine/topiramate and naltrexone/bupropion are also available, the 
first suppressing appetite and the mechanism of the latter not fully understood
25
.  The GLP-1 
analogue liraglutide has been shown to induce an average 5.6 kg weight loss
26
. More recently, 
studies of the GLP-1 analogue semaglutide demonstrated a dose-dependent weight loss up to 
11.5 % in comparison to placebo after one year
22
. A dual GLP-1 and glucose-dependent 
insulinotropic peptide (GIP) receptor agonist
27
 has been reported to induce a weight loss of 
more than 10% in up to 39 % of participants versus 9 % with the GLP-1 analogue comparator 
in patients with T2D and an average BMI of 32.6 kg/m
2
. Thus, the incretin analogues 
represent a novel approach in the pharmacological treatment of obesity, demonstrating 
promising effects that may change the field if not troubled by emerging major adverse effects.    
1.1.3.3 Bariatric surgery 
Bariatric surgery has been shown to induce substantial weight loss and decreased comorbidity 
and mortality
28
, making it the most effective treatment of obesity and associated comorbidity 
to date. Indications for bariatric surgery have been basically unchanged since the early 1990s, 
briefly constituting BMI > 40 kg/m
2
 or > 35 kg/m
2
 in combination with obesity associated 
comorbidity
29, 30
. According to a recent report
31
, 5400 patients underwent bariatric surgery in 
Sweden 2017. The most common bariatric surgery procedure was Roux-en-Y Gastric Bypass 
(RYGB) constituting 54.4 % of primary surgery, although sleeve gastrectomy increases  
(44.6 %). Laparoscopic technique was used almost exclusively, and perioperative severe 
complications rare (around 3 %) and 90-days mortality rates very low (0.4 ‰). Higher rates 
of severe adverse events have been reported in other studies with longer follow-up time
32
. 
The RYGB approach is illustrated in Figure 1. In sleeve gastrectomy, a part of the ventricle is 
removed. Pure restrictive procedures such as gastric banding have not been shown as 
effective
28
, and are now infrequently used. Degree of weight loss after surgery differs 
 4 
between surgical methods
28, 32
. RYGB and sleeve gastrectomy result in similar weight loss, 
on average around 30 % in the weight stable phase after two years
13, 28
. This is usually 
followed by weight regain during the following years, although not returning to the initial 
weight
28
.  
 
 
 
 
 
Figure 1. Roux-en-Y gastric bypass. A small pouch of the 
ventricle is created and attached to the distal jejunum, and 
the proximal “secretory limb” consisting of the remaining 
ventricle and duodenum is anastomosed back to the small 
bowel. Published with permission from the rights holder. 
 
 
 
 
 
 
In patients with obesity and T2D, there is a high degree of diabetes remission after bariatric 
surgery (Table 2). One meta-analysis reports improved diabetes control in ~90% of patients 
and diabetes remission in ~ 65 %
33
, although 19-53 % of the patients displayed diabetes 
relapse after 5-10 years
14, 34-37
. Comparative studies have shown RYGB to be a much more 
effective treatment of T2D than conventional medical treatment
13, 14, 38
, and bariatric surgery 
remains the most effective treatment of obesity and associated comorbidity to date.  
Bariatric surgery results in malabsorptive and restrictive effects. However, the favorable 
metabolic effects are also mediated by mechanisms beyond weight loss, including hormonal 
changes. Diabetes remission is often observed within the first post-operative week, i.e. before 
substantial weight loss has been achieved. Changes in the secretion of gastrointestinal 
hormones such as the incretins GLP-1 and GIP are thought to play a role in the early 
improvement of glycemic control
39-41
.  Independent of weight loss, the GLP-1 response to 
oral glucose intake increases markedly after gastric bypass
41, 42
. Accelerated nutrient flow in 
the intestines enhances incretin release from the ileum, in turn increasing insulin release and 
inhibiting gastric emptying
39
. 
1.1.3.4 Prediction of metabolic outcome and weight loss after bariatric surgery 
Given the increasing prevalence of obesity and its complication and that not all patients with 
obesity can undergo bariatric surgery, identification of patients who have the most to gain 
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from weight loss becomes a matter of great importance. To perform proper risk-benefit 
analyses before selecting treatment option, predictive factors and models are necessary.  
Most studies concerning prediction of metabolic improvement after weight loss focus on 
prediction of T2D remission after bariatric surgery. Less seem to be studied about predictors 
of improved insulin sensitivity or T2D incidence after weight loss in patients with prediabetes 
or without diabetes. Factors reported to predict T2D remission include markers of insulin 
production and sensitivity, BMI and age (Table 2). High age, long diabetes duration and 
insulin dependence are associated with a less degree of diabetes remission after weight loss. 
Different scoring systems for clinicians have been suggested. One of these suggested scoring 
system is DiaRem
43
 based on age, Hemoglobin A1c (HbA1c) concentration, use of 
sulfonylurea or other insulin sensitizing agent or insulin, that in one comparative analysis has 
been shown to have the best prediction error
44
. A more recent study has found similar 
predictors in larger cohorts with longer follow-up time
45
. Among adipose factors, adipocyte 
size has been shown to predict resolution of T2D or diabetes risk after weight loss
46
. 
Table 2. Remission rates of type 2 diabetes (T2D) after bariatric surgery and predictors of T2D remission  
Author, year Follow-up 
time (months) 
T2D remission rate Preoperative predictors of T2D 
remission 
Hayes et al 2011
47
 12  84 % HbA1c, fasting glucose, insulin treatment, 
BMI, hypertension 
Robert et al 2013
48
 12  62.8 % BMI, diabetes duration, HbA1c, fasting 
glucose, oral antidiabetic treatment 
without insulin 
Lee et al 2013
49
 12  65.3 % “ABCD score”: age, BMI, C-peptide, 
T2D duration 
Dixon et al 2013
50
 12  30.1 % (HbA1c < 
42 mmol/mol) 
BMI, T2D duration 
Ugale et al 2014
51
 Mean 12.7 and 
30.2 
depending on 
procedure  
46 % and 72 % 
depending on 
procedure/follow-up 
time 
Age, BMI, T2D duration, insulin 
treatment, stimulated C-peptide, micro 
and macrovascular complications 
Still et al 2014
43
 14 63 % “DiaRem score”: age, HbA1c, type of 
T2D medication, insulin treatment  
Aminian et al 
2017
45
 
84 49 % (gastric 
bypass) and 28 % 
(sleeve gastrectomy) 
T2D duration, number of T2D 
medications, insulin use, HbA1c 
Pucci et al
52
 2018 24 68.6 % “DiaBetter score”: HbA1c, T2D duration, 
type of T2D medication 
Partly adapted from Zhang et al
53
. BMI, body mass index; HbA1c, hemoglobin A1c; T2D, type 2 diabetes 
mellitus. 
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Few studies follow patients for more than ten years after bariatric surgery, and a limitation of 
many studies is low follow-up rates. There is limited data concerning the durability of 
diabetes remission after bariatric surgery
54, 55
. In the Swedish Obese Subjects study
28
, 2010 
obese subjects undergoing bariatric surgery and a similar number of matched controls 
receiving standard care have been followed up to 20 years. In the control group, the weight 
remained within 3 % around baseline values during follow-up, whereas a 13-27 % decrease 
was observed in the surgery group depending on procedure. Mortality rates were almost 30 % 
lower in the surgery group after 16 years, and despite a 50 % relapse after initial diabetes 
remission at the 10 years follow-up, the cumulative T2D incidence was at least 75 % lower in 
the surgery group
28
.  
1.2 ADIPOSE TISSUE 
There are two main forms of adipose tissue in mammals, white adipose tissue (WAT) and 
brown adipose tissue. WAT constitutes the great majority of human adipose tissue. Brown 
adipocytes are specialized in transforming stored fatty acids into heat by a “uncoupling” 
function enabling heat formation instead of adenosine triphosphate (ATP) generation by the 
action of uncoupling protein 1 (UCP-1)
56
. Results in recent years have also shown that there 
is also an intermediate form of fat that displays both white and brown phenotypes. This is 
sometimes referred to as “beige” adipose tissue. The metabolic impact of brown adipose 
tissue is debated in man, and brown and beige adipose tissue will not be discussed further in 
this thesis. 
Adipose tissue is composed of different cell types (Figure 2). While fat cells (adipocytes) 
make up to 90 % of the mass they only constitute 40-50 % of adipose tissue cell number. The 
rest of WAT is referred to as the stromal vascular fraction and includes mesenchymal stem 
cells, adipocyte precursor cells, endothelial cells, fibroblasts and immune cells such as 
macrophages and other leukocytes
57
. 
 
Figure 2. Histological section of white adipose tissue stained with hematoxylin and eosin. Adipose tissue 
consists primarily of adipocytes. The adipocytes store lipids in a large lipid droplet which constitutes most of the 
cell and pushes the nucleus and other organelles to the periphery. Between the adipocytes, other cell types 
including leukocytes, mesenchymal stem cells and preadipocytes are found in the stromal vascular fraction. 
Published with permission from Shutterstock.com.    
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Adipocyte hyperplasia 
Less proinflammatory adipokines 
Less inflammation 
Lower FFA release 
Less fibrosis 
Subcutaneous fat accumulation 
From previously being mainly regarded as an energy depot, WAT is now known to be an 
important organ contributing to the development of metabolic complications of obesity. 
Several observations illustrate that factors beyond a mere increase in fat mass per se are 
involved in the metabolic disturbances associated with obesity. For instance, surgical removal 
of fat does not induce favorable metabolic effects. Removing subcutaneous fat by liposuction 
does not improve metabolic profile
58
, and neither does removal of visceral WAT (i.e. the 
greater omentum) alone
59
 or in addition to RYGB surgery
60
. The absence of a functional 
adipose tissue is also detrimental, as illustrated by the condition lipodystrophy in which 
functional fat mass is lacking and insulin resistance observed
61
. Furthermore, the term 
metabolically healthy obesity has been used to reflect the fact that up to 30 % of obese 
patients display relative intact insulin sensitivity and lack of other metabolic complications
62
. 
However, the notion of metabolically healthy obesity has been questioned as there appears to 
be an increased risk of cardiovascular disease in this group compared to healthy non-obese, 
although lower than in “metabolically unhealthy” obesity63-65. Nevertheless, WAT mass 
expansion leads to a more pernicious phenotype, although these changes may be more or less 
pronounced as illustrated in Figure 3. A number of different adipose tissue factors contribute 
to the negative effects of expanding fat mass. These include alterations in distribution of body 
fat, adipocyte size and number, lipolysis, polypeptide (adipokine) secretion and inflammation 
as described in the following sections.  
 
 
 
 
Figure 3. Benign versus pernicious expansion of adipose tissue. Pernicious expansion of adipose tissue (right) 
is to a higher degree characterized by adipocyte hypertrophy, low grade inflammation including more abundant 
proinflammatory M1 adipose tissue macrophages than anti-inflammatory M2 macrophages, disturbed lipolysis 
with a higher release of free fatty acids (FFA) and development of fibrosis. “Crown-like structures” of M1 
macrophages surrounds the dead adipocytes. Figure from Choe SS et al
66
, slightly modified and published with 
permission. ATM, adipose tissue macrophages; FFA, free fatty acids. 
Adipocyte hypertrophy 
↑ Proinflammatory adipokines 
Low grade inflammation 
↑FFA release 
↑ Fibrosis 
Visceral fat accumulation 
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1.2.1 Body fat distribution 
Body fat distribution can be described in different ways. The most common classification of 
WAT based on its location is subcutaneous versus visceral adipose tissue. Subcutaneous 
adipose tissue constitutes more than 80 % of total body fat
67
. Body fat distribution can also be 
described as central versus peripheral, upper body versus lower body, abdominal versus 
gluteofemoral, or as android versus gynoid
68
. This latter terminology originates from the 
observation that men usually are more prone to abdominal fat accumulation whereas women 
in general have a tendency to gluteofemoral fat accumulation. The physiology behind these 
sex differences in body fat distribution includes estrogen effects, and a tendency towards 
more android fat accumulation is observed in women after menopause
69
. Intraabdominal 
visceral adipose tissue can be further divided into mesenteric and omental fat.    
Abdominal, and in particular visceral, WAT is highly associated with metabolic disturbances. 
As previously mentioned, abdominal obesity is one of the cornerstones of the metabolic 
syndrome and it associates with increased mortality independent of BMI
70, 71
. Whether 
abdominal obesity is causally linked to metabolic disturbances or rather a consequence or a 
marker of ectopic fat accumulation is not fully understood
72
. However, the potential 
pernicious properties of visceral fat accumulation may include several factors. The anatomic 
location of intraabdominal fat enables direct action of released adipokines and free fatty acids 
(FFA) on the liver through the portal vein, inducing hepatic insulin resistance and resulting in 
increased hepatic gluconeogenesis and very-low-density lipoprotein (VLDL) release and 
reduced insulin clearance, as formulated by Björntorp in the “portal theory”73. Basal lipolysis 
and catecholamine stimulated lipolysis is higher in visceral adipose tissue, the latter due to a 
dominance of β-adrenergic receptors74, and this has been correlated to metabolic 
disturbance
75
. Several further differences between visceral and subcutaneous adipose tissue 
are reported. Subcutaneous adipogenic capacity is higher than visceral
72
. Large inter-depot 
variations in macrophage numbers may contribute to differences in inflammation
67, 72
.  
In contrast to android fat accumulation, gynoid fat is considered protective
68
. The protective 
properties of WAT in the gynoid region may be mediated by its capacity to harbor excess fat 
and thus preventing ectopic fat accumulation and its negative metabolic consequences
67
.  
Body fat mass and distribution can be estimated or measured in several different ways.  
Simple methods such as waist circumferences, waist-to-hip ratio (WHR) and formulas based 
on age, gender and BMI
76
 can be used as indirect estimations. Bioelectrical impedance can be 
used to estimate total fat mass and fat free mass. Body fat mass and distribution can also be 
measured using magnetic resonance imaging (MRI) or x-ray based methods such as 
computed tomography (CT) and dual-energy x-ray absorptiometry (DXA).  
1.2.2 Adipocyte size and number 
As described above, adipocytes constitute less than half of the cell number in WAT. In 
weight stable adults, the number of fat cells is unaltered in adulthood although on average 10 
% of adipocytes are turned over, i.e. die and are renewed, each year
77
. With increasing fat 
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mass, adipocyte size increases. However, there is a limit for adipocyte size which implies that 
at some point, the number of adipocytes needs to increase as well. This is demonstrated by 
the curvilinear relationship between fat mass and fat cell size (Figure 4). It has been known 
since the 1970s that large adipocytes correlate with pernicious metabolic profile in cross-
sectional studies
78-80
. Adipocyte size has also been shown to predict future development of 
T2D independent of fat mass
81, 82
. After weight loss, fat cell size decreases but the fat cell 
number remains unaltered
77
.  
As adipocyte size is closely related to fat mass it has been difficult to determine the impact of 
fat cell size independent of body fat mass. A model based on the curvilinear relationship 
between fat cell size and fat mass has previously been suggested to isolate the effect of fat 
cell size independent of fat mass (Figure 4)
77
. If a curve is fitted into this graph, individuals 
can be described as having larger or smaller adipocytes than expected at any given fat mass. 
Thus, those above the fitted line have larger but fewer fat cells than expected (hypertrophy) 
whereas those below have more but smaller fat cells than expected (hyperplasia)
77
. The 
degree of hyperplasia or hypertrophy can be quantified using a morphology value which 
reflects the distance from the curvilinear fit. 
          
 
Figure 4. Adipose tissue morphology illustrated by the curvilinear relationship between fat mass and fat 
cell volume. At any given fat mass adipose tissue may consist of few but large adipocytes or many small 
adipocytes. Subjects above the fitted line can be classified as having an adipose tissue morphology characterized 
by hypertrophy, whereas those below as having hyperplasia. The morphology can be quantified by a morphology 
value, i.e. the vertical distance from the fitted line. Graph published with permission from the publisher
77
, 
pictures published with permission from Shutterstock.com. 
What mechanisms may explain the association between fat cell size and metabolic 
disturbances? Two principal different mechanisms are mainly suggested, the first involving 
local changes in adipose tissue phenotype and the other related to ectopic fat accumulation. 
With increasing fat cell size, adipokine expression turns into a more proinflammatory pattern 
with increased release of adipokines such as monocyte chemoattractant protein-1 (MCP-1) 
which recruits macrophages and induces a local low-grade inflammation promoting insulin 
 
 
 
Fat mass (kg) 
Hyperplasia 
(many small  
adipocytes) 
Hypertrophy 
(few large  
adipocytes) 
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resistance
83
. Hypertrophic adipocytes develop insulin resistance and are less sensitive to the 
inhibiting effect of insulin on the lipolytic processes resulting in increased basal lipolysis
84
 
and thus increased release of FFA. Another important role of subcutaneous adipose tissue is 
to store excess lipids to prevent ectopic lipid accumulation in liver, skeletal muscle and other 
organs where they may cause metabolic disturbances
85
. Inability of subcutaneous WAT to act 
as an “energy sink” promotes ectopic fat accumulation including visceral obesity with its 
associated negative metabolic consequences
86
. 
The process in which preadipocytes are differentiated into adipocytes is referred to as 
adipogenesis. The main regulator of adipocyte differentiation is the peroxisome proliferator-
activated receptor-γ (PPAR-γ)87, although other factors including insulin-like growth factor 1 
(IGF-1), insulin and glucocorticoids also induce differentiation
72
. The mechanisms 
determining development of hyperplasia or hypertrophy are not fully understood. It is likely 
to involve an inability to recruit and/or differentiate progenitor cells into mature adipocytes, 
i.e. impaired adipogenesis. The transcription factor early B-cell factor 1 (EBF1) has been 
shown to correlate with adipose morphology, with decreased expression and activity in 
hypertrophy
88
, and transforming growth factor-beta 3 has recently been shown to regulate 
subcutaneous adipocyte number
89
. 
In summary, impaired expandability of WAT by recruiting new adipocytes leads to WAT 
characterized by few but large adipocytes accompanied by a metabolically unfavorable 
clinical phenotype.   
1.2.3 Adipocyte function 
1.2.3.1 Lipogenesis and lipolysis 
Storage and release of lipids are major functions of adipocytes. Lipids are stored in the 
adipocytes in the form of triacylglycerides (TAG), and the controlled release of lipids through 
enzymatic breakdown of TAG, lipolysis, is an important mechanism in lipid metabolism.  
In times of energy excess, non-esterified FFA from the diet or hepatic de novo lipogenesis are 
taken up by the adipocyte through fatty acid transporter protein, and glucose enter the cell 
through the glucose transporter (GLUT) 4 upon insulin stimulation. FFA can also be 
synthesized from glucose through de novo lipogenesis within the adipocyte, although this 
process is probably of minor importance in adults. Glucose is metabolized into glycerol-3-
phosphate which is esterified with FFA eventually forming TAG that are stored in the large 
intracellular lipid droplets pushing the intracellular organelles to the periphery
90
 (Figure 2).  
In lipolysis, TAG are metabolized in three major steps by three distinct lipases, each releasing 
one fatty acid from the glycerol body (Figure 5). Glycerol is then released from the adipocyte 
since the cell lacks significant amounts of glycerol kinase and is thus unable to metabolize the 
glycerol molecule
91
. The rate-limiting step in human lipolysis is the release of the second 
fatty acid by hormone sensitive lipase (HSL) which is inhibited by insulin and stimulated 
primarily by catecholamines but also by natriuretic peptides, tumor necrosis factor alpha 
  11 
(TNF-α) and other factors91, 92. Catecholamines primarily stimulate lipolysis through β-
adrenergic receptors, but may also inhibit lipolysis through α-adrenergic receptors to a lower 
extent. Differences in lipolytic response to catecholamines between body fat regions are 
partly explained by variations in receptor density
74
. 
           Insulin            Catecholamines, natriuretic 
                                                  -        +       peptides, TNF-α etc. 
ATGL/HSL               HSL   MGL 
        TAG                 DAG        MAG                  Glycerol 
        FFA                          FFA                       FFA 
Figure 5. Schematic illustration of the hormonal regulation of human lipolysis. TAG are metabolized in 
three steps, each releasing one FFA. Insulin inhibits HSL while catecholamines and other substances stimulate 
lipolysis through HSL. ATGL, adipose triacylglyceride lipase; DAG, diacylglycerol; FFA, free fatty acid; HSL, 
hormone-sensitive lipase; MAG, monoacylglycerol; MGL, monoacylglycerol lipase; TAG, triacylglycerol; TNF, 
tumor necrosis factor. 
In patients with obesity, the basal lipolysis is increased. Concerning the catecholamine 
stimulated lipolysis in obesity, regional differences exists where visceral stimulated is 
increased while subcutaneous catecholamine stimulated lipolysis is decreased
92
. In the insulin 
resistant state, the activity of HSL is altered resulting in increased basal lipolysis and thus 
increased release of FFA further contributing to insulin resistance. In contrast, stimulated 
lipolysis is decreased which implies a decreased adaptability in the lipid metabolism
91
. These 
changes are believed to be a major contribution to the development of insulin resistance as 
further described below. The physiological importance of a functional lipolysis is illustrated 
in humans with mutations in the gene encoding HSL, which display insulin resistance, 
dyslipidemia and early development of T2D
93
. With increasing age, basal lipolysis is 
increased and stimulated lipolysis inhibited
92
. Lipolysis has been linked to long term 
development of T2D and weight development. Inflexible lipolysis, i.e. low stimulated and 
high basal lipolysis, predicts weight gain and insulin resistance
94
.  
1.2.3.2 Adipokines 
Adipose tissue is now recognized as an important endocrine organ. During the last decades 
more than 600 polypeptides have been described to be released from adipose tissue
57
. These 
factors are collectively termed adipokines. There is no consensus on whether this term should 
be reserved for factors only released from adipocytes or if those released from any cell type in 
adipose tissue could also be included
95
. Adipokines act within a broad range of different 
functional areas, including lipid turnover, inflammation, angiogenesis and regulation of blood 
pressure. However, the function of many adipokines still remains to be characterized.  
TNF-α was the first cytokine to be described as a WAT-secreted factor and associated with 
insulin resistance, secreted from adipocytes but primarily adipose tissue macrophages
96
. 
Adipose expression and levels of TNF-α have been shown to be increased in obesity and 
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correlate with insulin resistance, and decrease after weight loss
97
. TNF-α acts in a paracrine 
fashion in adipose tissue, interfering with several parts of intracellular insulin signaling, 
including insulin receptor substrate 1 (IRS-1)
98
, downregulating factors involved in the 
effects of insulin and inhibiting transcription of factors associated with insulin sensitivity 
99
.  
Leptin
100
, which is released from WAT and acts on the hypothalamus to regulate appetite 
and thus energy balance in an endocrine manner, was a seminal discover. Leptin levels are 
highly correlated to degree of obesity. Its implication as a therapeutic substance in obesity has 
been limited by the leptin resistance that quickly develops with increasing leptin levels
101
. 
Leptin levels in plasma correlate well with adipocyte size
102
. After weight loss, adipocyte 
leptin release is decreased below the control state
103
. 
Adiponectin is another well characterized adipokine. It displays an inverse relation to BMI 
and acts in an anti-diabetic manner by decreasing hepatic glucose production and increasing 
skeletal muscle fatty acid oxidation
104
. Low levels of adiponectin have been shown to predict 
future T2D development
105
. Although its effects are potent in murine models, the clinical 
relevance in man is disputed, and there are no therapeutic options targeting adiponectin.  
Interleukin 6 (IL-6) is released from adipose tissue and induces insulin resistance. Systemic 
levels of IL-6 can predict future T2D development
106
. IL-6 is also released from skeletal 
muscle and may mediate cross-talk between WAT and skeletal muscle
95
. The metabolic 
effects of IL-6 is probably dependent on whether the elevation of IL-6 is acute or chronic, as 
reviewed
107
. Acute IL-6 rise as in exercising muscle seem to reduce inflammation and 
promote insulin sensitivity whereas a chronic rise is associated with inflammation and 
reduced insulin sensitivity. Acute hyperinsulinemia induces elevated plasma IL-6 levels
108
.     
MCP-1 is a proinflammatory chemokine encoded by the CCL2 gene. MCP-1 is expressed in 
adipose tissue and attracts macrophages into adipose tissue. Its expression in adipose tissue is 
higher in obese state and higher in visceral than subcutaneous WAT. Circulating MCP-1 is 
elevated in patients with T2D
109
. 
1.2.4 Adipose inflammation 
As mentioned above, obesity is characterized by a chronic low grade inflammation in WAT 
induced by para- and autocrine pro-inflammatory molecules such as MCP-1, IL-6 and TNF-
α. These factors are released from the fat cells themselves as well as immune cells in the 
stromal vascular fraction, including macrophages recruited into WAT. Inflammatory 
molecules interfere with insulin signaling and induce insulin resistance as described above. 
The levels of MCP-1 correlate significantly with the percentage of infiltrating macrophages
83
. 
Traditionally, it has been considered that obesity induces a switch from alternatively activated 
anti-inflammatory “M2” macrophages to classically activated proinflammatory “M1” 
macrophages. The M1 phenotype is characterized by expression of proinflammatory markers 
such as TNF-α and IL-6, and is especially abundant in the “crown like structures” 
surrounding dead adipocytes (Figure 3). On the opposite, the M2 phenotype is characterized 
by anti-inflammatory markers
110
. However, this view seems to be simplistic and it has 
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recently been shown that metabolic dysfunction may drive the development of a specific 
metabolically activated macrophage phenotype
111
. In vitro experiments have shown that co-
culture of M1 macrophages and adipocytes make macrophages turn in to a more M2 like 
phenotype
112
.  
WAT inflammation is diminished after weight loss, with decreased number of 
macrophages
113
 and decreased adipocyte expression of inflammatory proteins such as  
TNF-α97, 114. 
1.2.5 Adipose fibrosis 
Development of fibrosis is another characteristic of metabolically unhealthy expanded WAT. 
Rapidly expanding adipose tissue leads to hypoxia which induces excessive synthesis of 
extracellular matrix components including collagens. Fibrosis is linked to inflammation and 
infiltration of macrophages
115
. In fibrotic areas, alternatively activated M2 macrophages are 
abundant in the adipose tissue of obese subjects and correlate with insulin resistance
112
.  
1.3 INSULIN 
1.3.1 Insulin synthesis and secretion 
Insulin is a 5.8 kDa protein composed of 51 amino acids synthesized in the pancreatic β-cells. 
It is initially synthesized as preproinsulin, and then processed to proinsulin in the 
endoplasmic reticulum before cleaved into insulin and C-peptide in the Golgi apparatus and 
eventually stored in granules awaiting proper stimulus for release. Insulin synthesis and 
release into the circulation is primarily regulated by glucose. Glucose enters the beta cells 
through GLUT2, which responds even to small changes in the blood glucose concentration, 
thus tightly regulating insulin secretion during physiological conditions. Glucose is 
metabolized through glycolysis after entering the cell, and ATP formed which in turn acts on 
ATP-sensitive potassium channels which increases intracellular levels of potassium and 
depolarizes the cell. This causes voltage-sensitive calcium channels to increase calcium 
influx which finally induces exocytosis of granules containing insulin, releasing insulin into 
the circulation. Insulin secretion is also regulated by FFA, GLP-1 and other factors. GLP-1 
increases insulin secretion.
116
 
1.3.2 Insulin signaling and effects 
Insulin exerts its effects through a tetrameric membrane spanning tyrosine kinase receptor. 
Upon insulin binding, the receptor is autophosphorylated which activates the tyrosine kinase 
activity of the receptor. This initiates the intracellular signaling pathway, including 
phosphorylation of IRS-1, activating phosphatidylinositol-3 kinase and eventually the protein 
kinase Akt, mediating the intracellular effects of insulin. Intracellular insulin signaling is 
complex and involves many different pathways resulting in many different events.   
In the liver, insulin inhibits glycogenolysis and gluconeogenesis and thereby the subsequent 
efflux of glucose from hepatocytes through the GLUT2 into the circulation. In skeletal 
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muscle, insulin (and physical activity) induces the translocation of GLUT4 to the cell 
membrane which facilitates glucose uptake into myocytes. Although skeletal muscle is the 
major target organ for insulin stimulated glucose uptake, GLUT4 is also responsible for the 
insulin stimulated glucose uptake into adipocytes
117
. By inhibiting HSL, insulin promotes the 
storage of lipids in the adipocytes.  
1.3.3 Insulin resistance 
The progress from normal glucose metabolism to T2D involves a progressive impairment of 
insulin sensitivity in different organs paralleled by increased endogenous insulin release from 
the pancreatic beta cells that initially compensate for the insulin resistance. But with long- 
standing insulin resistance the beta cells gradually fail in this compensation and relative 
insulin deficiency develops which results in impaired fasting glucose, impaired glucose 
tolerance and eventually T2D
118
.  
Central organs involved in the development of and affected by the consequences of insulin 
resistance include the pancreas, liver, skeletal muscle and adipose tissue
119
, as illustrated in 
Figure 6. Chronic elevation of circulating FFA causes ectopic lipid accumulation in 
peripheral organs such as liver, skeletal muscle and pancreas. This induces negative 
metabolic consequences described as lipotoxicity. The consequences of hepatic insulin 
resistance include decreased glycogenesis and decreased inhibition of glycolysis and 
gluconeogenesis resulting in increased glucose production and output, and increased release 
of VLDL. In skeletal muscle, insulin resistance causes decreased uptake of glucose. In 
adipose tissue, the effects of insulin resistance include decreased inhibition of basal lipolysis 
leading to excess release of FFA.  
FFA impair insulin sensitivity in a dose-dependent manner in humans
120, 121
. One of the first 
proposed mechanisms to explain insulin resistance was the Randle hypothesis
122
, stating that 
increased FFA influx and fatty acid oxidation cause increased levels of acetyl coenzyme A, 
inhibit pyruvate dehydrogenase and thus reduce glucose oxidation and increase levels of 
citrate. This causes inhibition of the rate limiting step in glycolysis (phosphofructokinase), 
eventually causing increased intracellular glucose levels and decreased glucose uptake. Later 
studies have shown that this mechanism may not be entirely correct, and rather stress the 
importance of diacylglycerols (DAG) arising from increased influx of FFA into the cell. 
DAG activate protein kinase C, which in turn inactivate IRS-1 through phosphorylation and 
thereby inhibit the insulin signaling pathway causing decreased glucose uptake and 
breakdown
123
. 
As described in previous sections, inflammation is another feature promoting insulin 
resistance. TNF-α interferes with insulin signaling through interaction with IRS-198 and 
stimulates lipolysis through HSL
99
. MCP-1 induces insulin resistance in adipocytes with 
reduced glucose uptake, and also promotes insulin resistance in non-adipose tissue
83
. 
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Figure 6. Causes and consequences of insulin resistance in obesity. In the obese state, the release of free fatty 
acids (FFA) from adipose tissue increases. By paracrine actions, FFA and proinflammatory adipokines from 
enlarged adipocytes induce insulin resistance in adipose tissue which increases lipolysis enhancing the flux of 
FFA tissue into the circulation. By interfering with intracellular insulin signaling pathways, FFA induce insulin 
resistance in liver, muscle, pancreas and other organs. In the liver, insulin resistance induces increased glucose 
output and release of very-low-density lipoproteins. In skeletal muscle, insulin resistance leads to increased FFA 
utilization and decreased glucose uptake. These changes induce hyperglycemia, which triggers increased insulin 
release from the pancreas resulting in hyperinsulinemia. FFA, free fatty acids; VLDL, very-low-density 
lipoproteins. Pictures published with permission from Shutterstock.com. 
The hyperinsulinemia resulting from insulin resistance is also per se considered to drive the 
development of insulin resistance. Chronic hyperinsulinemia is believed to contribute to 
insulin resistance by inducing inflammation in adipose tissue and thereby increasing lipolysis;  
by increasing lactate formation in muscle and thereby increasing hepatic gluconeogenesis; 
and by stimulating hepatic lipogenesis
117
. 
Taken together, all the changes discussed above promote insulin resistance if energy excess is 
sustained. 
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The clinical consequences of insulin resistance and T2D include the micro- and 
macrovascular complications of diabetes. T2D is associated with an approximate two-fold 
increased risk for cardiovascular disease
124
. Even hyperinsulinemia has been linked to 
increased risk of cardiovascular disease
125
, and a slight increased risk for cardiovascular 
disease has been observed even at modest elevated blood glucose levels
124
.   
1.3.4 Measuring insulin sensitivity 
1.3.4.1 Hyperinsulinemic euglycemic clamp 
The hyperinsulinemic euglycemic clamp method to measure insulin sensitivity was presented 
in 1979
126
. During a continuous insulin infusion, a simultaneous glucose infusion maintains 
euglycemia. High levels of insulin are required to fully suppress the hepatic glucose 
production. Since the hepatic glucose production is assumed to be switched off, the procedure 
reflects whole body insulin sensitivity. The amount of glucose infused corresponds to the 
glucose disposal rate (GDR) or metabolizable glucose (M), reflecting whole body insulin 
sensitivity. A GDR of 4.9 mg/kg/min has been suggested as a cut-off for insulin resistance in 
the 0.12 U insulin/m
2
/min setup
127
. Hyperinsulinemic euglycemic clamp is further discussed 
in chapter 3.5. 
1.3.4.2 Homeostatsis Model Assessment of Insulin Resistance (HOMA-IR) 
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
128
 is a mathematical 
formula to estimate insulin sensitivity, based on fasting plasma levels of glucose and insulin. 
It is calculated as follows:  
HOMA-IR = fasting plasma glucose (mmol/l) x fasting plasma insulin (mU/l) / 22.5 
HOMA-IR correlates well with hyperinsulinemic euglycemic clamp
128
. Reflecting normal 
fasting values for insulin and glucose, HOMA-IR is around 1 at physiological conditions. 
Proposed limit for insulin resistance has been a value above the 75
th
 percentile in a population 
without diabetes
8
, usually HOMA-IR ≥ 2.564, 129.  
1.3.4.3 Other methods to determine insulin sensitivity 
Oral Glucose Tolerance Test (OGTT) assesses the blood glucose response to an oral bolus of 
glucose and provides a relatively simple method able to detect early disturbances in glucose 
metabolism
130
.  
Glucose tolerance tests can also be performed through intravenous administration of glucose, 
a method less influenced by gastrointestinal glucose uptake. In the Frequently Sampled 
Intravenous Glucose Tolerance Test (FSIVGTT), glucose is infused and frequent samples of 
insulin and glucose collected. Using the minimal model assessment, a sensitivity index 
reflecting insulin sensitivity can be calculated
131
. 
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Insulin Tolerance Test (ITT) is another measure of insulin sensitivity validated against 
clamp
132
. After an intravenous insulin infusion, the measured plasma glucose disappearance 
rate offers an assessment of insulin sensitivity.   
In addition to HOMA-IR, there is another fasting index to determine insulin sensitivity. In the 
Quantitative Insulin Sensitivity Check Index (QUICKI) fasting values of insulin and glucose 
are log-transformed, and the index can be calculated using the formula 1 / [log (fasting 
plasma insulin) + log (fasting plasma glucose)]. QUICKI has been validated against 
hyperinsulinemic clamp and FSIVGTT
133
.
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2 HYPOTHESES AND AIMS 
2.1 GENERAL AIM 
The general aim of this thesis is to further characterize the relationship between WAT 
characteristics and metabolic parameters, cross-sectionally before and after weight loss, and 
to investigate if WAT phenotype can predict changes in metabolic parameters after weight 
loss. 
2.2 SPECIFIC HYPOTHESES AND AIMS 
2.2.1 Study I 
Rationale: Proper selection criteria for bariatric surgery are of great importance from 
individual and societal view in order to make proper risk-benefit analyses. Current selection 
criteria based on BMI has a limited ability to predict metabolic outcome after RYGB, and 
better predictors of metabolic outcome are needed.  
Hypothesis: Large adipocytes and adipose hypertrophy predicts improved insulin sensitivity 
after weight loss.  
Aim: To investigate if adipose tissue morphology or fat cell size can predict improved insulin 
sensitivity after weight loss. 
2.2.2 Study II 
Rationale: WAT and clinical phenotype improve after RYGB. However, less is known about 
the degree of improvement in relation to weight stable subjects.  
Hypothesis: Subjects that have undergone RYGB have a more favorable metabolic and WAT 
phenotype than weight stable control subjects. 
Aim: To compare the clinical and WAT phenotype in RYGB patients after weight loss with 
weight stable control subjects. 
2.2.3 Study III 
Rationale: Characterization of protein release from WAT may facilitate further understanding 
of the mechanisms behind metabolic alterations in obesity and identify markers of metabolic 
disturbance. CC chemokine ligand 18 (CCL18) expression in WAT has been reported to be 
upregulated in obesity and diabetes, and related to inflammation and fibrotic disease in other 
tissue types.  
Hypothesis: CCL18 is associated with metabolic disturbance, secreted from subcutaneous 
adipose tissue and exert effects on WAT cells promoting extracellular matrix formation and a 
proinflammatory response.  
 20 
Aim: To investigate if CCL18 is secreted from subcutaneous adipose tissue. To determine if 
adipose secreted or circulating CCL18 correlate with metabolic parameters. To determine the 
cellular origin of CCL18 in WAT and investigate the potential effects of CCL18 on 
adipocytes and macrophages in vitro. 
2.2.4 Study IV 
Rationale: Better predictors of metabolic outcome and weight loss after RYGB are needed to 
improve candidate selection for RYGB. Body fat distribution is associated with metabolic 
dysfunction.  
Hypothesis: DXA measured body fat mass and distribution can predict weight loss and 
improved insulin sensitivity, hypertension or dyslipidemia after RYGB. DXA measures are 
superior to basic anthropometric measures as predictors of these outcomes.   
Aim: To investigate if preoperative body fat mass and/or distribution determined by DXA can 
predict improved metabolic parameters and/or weight loss after RYGB, and to compare 
predictive value of DXA with basic anthropometric measures. 
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3 METHODOLOGICAL ASPECTS 
3.1 STUDY DESIGN 
Study I was a prospective interventional cohort study in which two cohorts were examined 
before and after weight loss induced by diet or RYGB respectively. Baseline adipose tissue 
morphology and adipocyte size were studied as predictors of changes in insulin sensitivity 
after weight loss. A third cohort was used to enable calculations of adipose morphology. 
Study II was a prospective interventional cohort study with matched controls. Patients were 
examined before, two and five years after weight loss. At the five year follow-up, patients 
were matched on BMI, sex and age with control subjects and clinical and adipose parameters 
compared.   
Study III was a cross-sectional cohort study. CCL18 expression and release were correlated to 
clinical parameters, and effects of recombinant CCL18 on adipocytes and macrophages 
studied in vitro.   
Study IV was a prospective interventional cohort study where patients were examined before 
and two years after RYGB. Baseline DXA measures and anthropometric measures were 
studied as predictors of improved metabolic parameters after weight loss.   
3.2 CLINICAL COHORTS 
Several cohorts are included in this thesis and one of the cohorts is used in three studies 
herein, as presented in Table 3 and the text below. More detailed clinical characteristics of 
each cohort are described in each manuscript respectively.  
Table 3. Study specific presentation of cohorts included in this thesis. Cohorts are further described in the 
text following the table. 
 Longitudinal cohorts Cross-sectional cohorts 
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Study I x x          x    
Study II  x      
Study III  
 
       x       x
 
      x 
Study IV  x x     
NUGENOB (Nutrient-Gene Interactions in Human Obesity) was a European randomized 
study on the metabolic effect of either of two hypocaloric diets in overweight or obese but 
otherwise healthy subjects
134
. In study I, 21 men and 79 women from the NUGENOB study 
were included.  
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DEOSH (Danderyd Ersta Oment Södertälje Huddinge) is a multi-center randomized 
controlled trial primarily investigating the metabolic effects of omentectomy in addition to 
RYGB
60, 135
 (clinicaltrials.gov NCT01785134). 82 women with obesity were examined at 
baseline, 62 women two years after RYGB and 49 women five years after follow-up. 
Exclusion criteria were T2D with insulin or glitazone treatment, oral or parenteral steroid 
treatment, complicated psychiatric disease and warfarin use. This study also includes a 
matched control group.  
NEFA (Non-Esterified Fatty Acids / New Fat study) is a longitudinal study of the metabolic 
and adipose tissue effects after RYGB (clinicaltrials.gov NCT01727245). Exclusion criteria 
were the same as in DEOSH described above. 133 women that were examined on baseline 
and 104 followed up after two years are included in study IV.  
The DPP4 (Dipeptidyl Peptidase 4) cohort was originally used in a study that identified 
DPP4 as a novel adipokine
136
. It consisted of 10 non-obese patients and 19 obese women. 
The RIKEN cohort included 30 obese and 26 non-obese patients, original involved in a study 
of adipose tissue microRNA as regulators of CCL2 production
137
. Transcriptomic and other 
analyses where performed at the RIKEN research institution in Japan. 
EMIF (European Medical Information Framework) is a large pan-European research 
collaboration in which this cohort has been a part. The cohort used herein is based on a group 
of 220 women in which the upper and lower extremes (n = 40 + 40) of insulin sensitivity as 
measured by HOMA-IR are compared. Further clinical details on this cohort have been 
published
138
. 
3.3 CLINICAL EXAMINATIONS 
Subjects arrived at the research center in the morning after an overnight fast. They had been 
instructed to avoid physical activity from the day before the examinations and smoking or 
other nicotine use in the morning. Patients in the bariatric surgery cohorts were examined 
within three weeks before surgery. A digital scale (TANITATBF-305) was used to measure 
weight to the nearest 0.5 kg, and height was measured to the nearest 0.5 cm. Waist and hip 
circumferences were measured. Venous blood samples were drawn for further analyses. Low-
density lipoprotein (LDL) cholesterol was calculated using the Friedewald´s formula with 
values expressed in mmol/L (cholesterol - high-density lipoprotein - 0.45 x triglycerides)
139
. 
An automatic device was used to measure blood pressure in the right arm (Omron M10-IT, 
Omron Health Care, Hoofddorp, the Netherlands). ATP III-score used in Study III were 
based on the ATP III definition of the metabolic syndrome (Table 1), with one point given for 
each criteria fulfilled or medication for any risk factors. 
3.4 MEASURING BODY FAT MASS AND DISTRIBUTION 
In this thesis, body fat mass was measured by DXA or bioelectrical impedance, and 
calculated by the use of a formula as described below.  
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3.4.1 Dual-energy X-ray absorptiometry (DXA) 
DXA was used to determine body fat mass and distribution (GE Lunar iDXA, GE 
Healthcare, Madison, WI, USA). The enCORE software (version 14.10.022, GE Healthcare, 
Madison, WI, USA) enabled determination of fat mass and percentage within different fat 
depots, i.e. android and gynoid fat. The android region is defined by the software as the 
region between the pelvis cut line, a line 20 % of the distance between the pelvis and neck cut 
line and laterally by the arm cut line (Figure 7). “Estimated subcutaneous adipose tissue” 
(ESAT) is assessed within the android region. The CoreScan feature (GE Medical Systems, 
Chalfont St. Giles, UK) was used to estimate visceral fat amount. “Estimated visceral adipose 
tissue” (EVAT) mass is assessed within the android region (total android fat mass - 
ESAT)
140
, thus only constituting the visceral fat within the android region as illustrated in 
Figure 7. Throughout the study, daily automatic calibration checks of the DXA machine were 
performed. A spine phantom provided by the manufacturer was used for regular calibrations 
three times a week.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Dual-energy X-ray absorptiometry examination before (left) and after (right) Roux-en-Y gastric 
bypass. The android (red box) and gynoid region (green box) is indicated as defined by the software. Published 
with permission from the patient. 
DXA measure of body fat allows fast examinations with low radiation exposure in 
comparison to CT scan, one of the reference methods. In a comparative study, DXA 
measures of visceral fat correlated well with values from CT scan (r
2
 value 0.959 for 
women)
140
, and this assessment of visceral fat mass is approved by the US Food and Drug 
Administration for clinical use. In comparison to MRI in the study of patients with obesity, 
DXA do not suffer from the limitation that a substantial proportion of patients do not fit into 
the MRI scan
141
.  
Gynoid  
region 
Android  
region 
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3.4.2 Bioelectrical impedance 
In study I, body fat percentage was determined by bioelectrical impedance (Body Stat, Quad 
Scan 4000, Isle of Man, British Isles). The precision of bioelectrical impedance analyses is 
considered sufficient to estimate body composition at group level, although a tendency 
towards a few percent underestimation of fat mass in the obese and overestimation to a 
similar degree in the lean is reported in comparison to DXA. This trend towards 
underestimation of fat mass in comparison to DXA was also seen in a cohort included in the 
same multicenter study as cohort 1 in study I, although there was a strong correlation between 
bioelectrical impedance and DXA values (r=0.78)
142
 . 
3.4.3 Formula 
In study IV, body fat percentage was also calculated in addition to being measured by DXA. 
The following formula, based on BMI, age and gender was used
76
: 
age x 0.13 + 1.5 x BMI -11.5 (for women)  
3.5 DETERMINATION OF INSULIN SENSITIVITY 
Insulin sensitivity was determined by HOMA-IR and hyperinsulinemic euglycemic clamp in 
this thesis. 
Insulin levels were determined by enzyme-linked immunosorbent assay (ELISA) as 
described below, and HOMA-IR calculated using the formula (fasting plasma glucose 
(mmol/l) x fasting plasma  insulin (mU/l) / 22.5).  
During the hyperinsulinemic euglycemic clamp, a constant insulin infusion is administered 
paralleled by a variable glucose infusion to maintain euglycemia. In our setup, a 1.6 units/m
2 
body surface area bolus dose of insulin (Actrapid, Novo Nordisk, Copenhagen, Denmark) 
was administered intravenously, followed by a continuous intravenous insulin infusion at a 
rate of 0.12 units/m
2
 body surface area/minute during two hours. The insulin was suspended 
in 82 ml sodium chloride (9 mg/ml), 2 ml albumin (200 g/l, Albunorm Octapharma, 
Stockholm, Sweden) and 16 ml potassium chloride (2 mmol/ml) to avoid hypokalemia. The 
infusion rate was 25 ml/h. This was accompanied by a 200 mg/ml variable glucose infusion 
to maintain euglycemia (4.5 - 5.5 mmol/L). Arterialized blood samples were collected from 
the dorsal side of the hand, kept in a heating box (63
o 
C), and analyzed in duplicates every 
fifth minute (Hemocue, Ängelholm, Sweden) to determine blood glucose values throughout 
the procedure. Glucose disposal rate during steady state was quantified by the calculated M-
value (mg/kg*min), based on the glucose infusion rate during steady state the last hour of the 
clamp. 
Hyperinsulinemic euglycemic clamp has been considered gold standard to measure insulin 
sensitivity, although disadvantages of the method include that it is quite time consuming and 
expensive. Besides, the term “gold standard” may be misleading since different measures of 
insulin sensitivity reflect different aspects of insulin sensitivity. Since skeletal muscle is the 
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primary target for insulin stimulated glucose uptake, clamp measurement of insulin 
sensitivity are highly dependent on factors associated with glucose uptake by skeletal muscle 
including muscle mass and physical activity. In contrast to the hyperinsulinemic euglycemic 
clamp, HOMA-IR relies on the relationship between hepatic glucose output and insulin 
secretion in the fasting state and primarily reflects hepatic insulin sensitivity. HOMA-IR has 
been reported to correlate well with hyperinsulinemic clamp
143
, although another study found 
a lower correlation and suggests that oral glucose tolerance test may better reflect insulin 
stimulated glucose uptake
144
. The M-value can be indexed on insulin levels during the clamp 
or lean body mass, and thereby reflecting slightly different aspects.  
In our clamp setup, the insulin infusion rate used was 0.12 U/m
2
/min. This relatively high rate 
was chosen to achieve a complete suppression of endogenous glucose production even in 
morbid obesity, and to reach steady state more quickly as discussed
127
. Since endogenous 
hepatic glucose production is assumed to be shut off due to the high concentration of insulin, 
administered exogenous glucose is expected to reflect whole body glucose uptake (primarily 
by skeletal muscle), but to be sure would require studies involving radioactively labelled 
glucose.   
3.6 ADIPOSE TISSUE EXAMINATIONS 
3.6.1 Subcutaneous adipose tissue biopsies 
Biopsies were performed approximately 15- 30 cm laterally from the umbilicus. Under sterile 
conditions, 20 ml of prilocaine hydrochloride (5 mg/ml) without epinephrine was injected 
subcutaneously. After local anesthesia was achieved, a minor incision was made and 
subcutaneous adipose tissue vacuum aspired using a needle and a 10 ml syringe. Tissue 
samples were rinsed with saline over a plastic filter (Sefar Nitex 06-210/33, Bigman AB, 
Sweden) and contaminating coagulated blood removed manually using a spatula. Samples 
were immediately transported to lab, rinsed in saline and analyzed immediately or frozen in 
liquid nitrogen for storage in -70 degrees C for later protein analyses. The biopsy procedure 
with needle aspiration under local anesthesia has previously been shown not to affect 
adipocyte metabolism
145
.  
3.6.2 Fat cell isolation and determination of adipocyte size 
Subcutaneous adipose tissue samples were kept in sodium chloride during transport to the 
lipid laboratory for further analyses. Samples were washed again as described above, and 
thereafter further washed several times with a washing buffer (Krebs Ringer Phosphate buffer 
with 1 % and 0.1% bovine serum albumin respectively). To separate adipocytes from the 
stromal vascular fraction, samples were incubated in a buffer with 0.5 mg/ml collagenase and 
4 % bovine serum albumin in a 37
°
C water bath. Thereafter, cells were washed again and 
filtered through a nylon filter three times.  
Determination of fat cell size was made in accordance to Rodbell
146
. After collagenase 
treatment, a droplet of the cell suspension was examined in direct light microscope where the 
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diameter of 100 cells was measured using a ruler in the ocular of the microscope. The mean 
adipocyte volume was estimated from the diameter by a formula taking into account that the 
cells are spheric
147
. The method used for determination of adipocyte size has been used by 
our laboratory for decades and correlates well to measure of adipocyte size in sliced 
sections
148
. 
In study I, a morphology value (i.e. quantification of the deviation of adipocyte size from the 
expected size at any given fat mass) was calculated for each subject. For cohort I, 
morphology values were available from a previous study
149
. To enable calculations of 
morphology values in cohort 2 where fat mass was measured by DXA, a third cohort with 
subjects having a broad range of fat mass was added and a line fitted to describe the 
curvilinear relationship between fat mass and adipocyte size. The least squares non-linear 
fitting was used to describe the curve with the following formula: 
V = (31.6 x m)/(1 + 0.0161 x m) 
Where V = mean fat cell volume (picoliters), and m = fat mass (kilograms). Morphology 
value was calculated by subtracting the expected fat cell mass from the measured.     
3.6.3 Measurement of lipolysis 
Lipolysis is assessed through the measurement of glycerol release. Since glycerol is not 
metabolized in adipocytes due to the lack of glycerol kinase, glycerol release is directly 
related to the lipolytic activity in contrast to the other end product of lipolysis, FFA, which 
may become re-esterified. In study II, glycerol release from intact pieces of subcutaneous 
adipose tissue was analyzed. Pieces of adipose tissue (100 mg/ml medium) were put into 
Krebs-Ringer phosphate buffer (pH 7.4) supplemented with glucose (1 mg/ml), bovine serum 
albumin (20 mg/ml) and ascorbic acid (0.1 mg/ml), and incubated at 37°C in 2 hours. 
Aliquots of the medium were subsequently removed for determination of glycerol release. 
Glycerol release was determined by bioluminescence as described
150
. In this assay, glycerol 
kinase consumes added ATP when breaking down glycerol, and the residual ATP is 
quantified through a Luciferase catalyzed reaction of ATP and luciferin in which light is 
emitted. 
In study II, glycerol release was assessed from tissue pieces rather than isolated fat cells, 
which enables assessment under more physiological conditions, with the stromal vascular 
fraction and the structure of the tissue better preserved. However, assessment of stimulated 
lipolysis would require isolation of adipocytes. Glycerol release is usually normalized on 
triglyceride mass or number of fat cells. In study II, fat cell number is calculated based on 
lipid weight of the incubated WAT divided by mean fat cell weight. Glycerol release was also 
expressed in relation to the amount of ESAT, providing a potential estimate of the systemic 
effects.    
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3.6.4 Gene expression analyses 
Polymerase chain reaction (PCR) was used in study III to determine expression of the 
specific genes of interest. The qPCR technique enables a quantitative determination of gene 
expression. RNA was isolated, cDNA synthesized and quantitative PCR performed. The 
ΔΔCt method was used to analyze gene expression, and LRP10 and 18S rRNA and were used 
to normalize the expression of analyzed genes in adipocytes and THP-1 cells respectively.  
Microarray data were used for analyses of gene expression in intact adipose tissue in cohort 2 
in study III. Microarray data were obtained by the usage of Human gene 1.0 ST Array 
(Affymetrix, Inc., Santa Clara, CA, US), and processes were performed using standardized 
protocols. Microarray offers the possibility to perform a genome wide characterization of 
gene expression and to perform gene ontology analyses. In comparison to other approaches 
such as Cap Analyses of Gene Expression (CAGE), microarray is cheaper and requires a 
smaller sample size.   
3.6.5 Determination of protein release 
ELISA was used to determine levels of serum insulin and levels of proteins released from 
adipose tissue, including CCL18. ELISA enables a quantitative determination of protein 
levels. In comparison to Western blot, ELISA is faster to perform and offers a highly 
quantitative approach. Depending on factors including antibody clonality, analyses may vary 
in terms of sensitivity and specificity. All analyses were performed according to the 
instructions from the manufacturer. The CCL18 assay used (R&D Systems Inc., Minneapolis, 
USA) is based on the quantitative sandwich enzyme immunoassay approach, with 
monoclonal antibodies covering the microplate and polyclonal enzyme-linked antibodies 
used for detection. Linear increase of protein with incubation time indicates secretion from 
WAT. 
3.6.6 Cell cultures 
In study III, cell cultures of in vitro differentiated preadipocytes were used. In contrast to 
freshly isolated adipocytes, in vitro differentiated preadipocytes offers the advantage of being 
able to attach to wells and being cultured for longer time. Additionally, freshly isolated 
adipocytes are fragile although they may better reflect in vivo conditions. THP-1 cells, also 
used in study III, are derived from an immortalized monocyte cell line that can be 
differentiated into macrophages in the M0, M1 or M2 spectrum
110
, offering an in vitro model 
of macrophages although there may be differences in comparison to adipose tissue derived 
macrophages.      
3.7 ROUX-EN-Y GASTRIC BYPASS 
In the DEOSH cohort, open RYGB was performed as described
60
. After an upper midline 
incision, a small gastric pouch (20–30 ml) was created and sealed by linear staples. The 
gastro-entero anastomosis was created by linear or circular staples, and the entero-entero 
anastomosis by linear staples. The alimentary and biliopancreatic limbs were typically 120 
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and 75 cm long, respectively. Half of the patients in the DEOSH study were randomized to 
omentectomy, where the entire greater omentum was surgically resected during the same 
session. In the NEFA study, patients primarily underwent laparoscopic surgery.   
3.8 STATISTICAL ANALYSES 
In all studies, absolute values were presented as mean ± standard deviations. Depending on 
data distribution and whether data were dependent or not, different tests were used to 
compare data as presented in Table 4. 
Table 4. Statistical tests used to compare two data sets 
Data type Parametric Non-parametric 
Unpaired/independent (Student´s) t-test Mann-Whitney U-test (Wilcoxon 
rank sum test) 
Paired/dependent Paired (Student´s) t-test Wilcoxon signed rank test 
Study I. Comparisons between groups were made by unpaired t-test or Mann-Whitney U-test 
depending on data distribution, and by paired t-test for intraindividual comparisons of values 
before and after weight loss. Spearman correlation tests were used to determine the 
correlation between continuous predictors and outcomes. 
Study II. Longitudinal comparisons between intraindividual values and values between post-
obese patients and matched controls were made using paired Students t-test or Wilcoxon 
signed rank test. Comparisons between post-obese subjects and controls were also made by 
unpaired t-test. Analysis of covariance (ANCOVA) was used for comparison of the relation 
between serum adiponectin and HOMA-IR between the post-obese subjects and controls. 
Linear regression was used to investigate potential predictive properties of values at two 
years versus changes between two and five years, and to determine potential associations 
between changes in different parameters between two and five years. 
Study III. Comparisons between groups were made with tests in accordance to Table 4. Non-
parametric data were log10 transformed to achieve normal distribution. Linear regression was 
used to determine potential correlations between different parameters. Multiple regression 
analyses were used to adjust for BMI.  
Study IV. Shapiro-Wilks test was used for assessment of normal distribution, and two-sided 
statistical tests were chosen in accordance to Table 4. Linear regression was used to correlate 
predictors (baseline parameters) with outcome (changes in metabolic parameters). Multiple 
regression analyses were used to adjust for potential confounders (BMI and age) and to 
compare the predictive value of DXA measures with basic anthropometric values. 
Both study I and IV revolves around prediction. In study I, the predictors are reported both as 
a binary and continuous variable, whereas study IV investigates continuous predictors. Both 
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studies have continuous outcomes. Alternatively, the outcome could have been dichotomized 
into a binary outcome, enabling the construction of a receiver operating characteristic (ROC) 
curve which offers a measure of predictive accuracy, i.e. the area under the curve. 
Disadvantages of dichotomizing the outcome may however include the risk of an arbitrary 
cut-off and that information about degrees within the parameter. Dichotomizing both the 
predictors and outcomes would enable assessment of predictive accuracy in terms of 
sensitivity, specificity and positive and negative predictive value. It may be an alternative 
approach but would expand the challenges discussed above to the predictor as well. To assess 
prediction, Spearman correlation test was used in study I and linear regression in study IV. 
Spearman correlation test makes fewer assumptions than linear regression. A linear 
regression model enables (more or less precise and valid) reproductions of the prediction. The 
rho and r
2
 values offer an indication of the precision of the predictor.  
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4 RESULTS 
Findings are presented in detail in each respective manuscript. Study specific summary of the 
results are presented in the following sections. Figure 10 summarizes the major findings of 
the studies.  
4.1 STUDY I 
In cohort I, 100 patients (79 women and 21 men) were included. 61 patients were included in 
cohort II and examined before and two years after RYGB. At baseline, patients were 
classified as having an adipose morphology characterized by hypertrophy or hyperplasia. In 
both cohort I and II, patients with hypertrophy displayed higher HOMA-IR (P = 0.003 in 
cohort 1 and 0.0006 in cohort 2), insulin (P < 0.0001 and 0.004 respectively) and WHR (P = 
0.013 and 0.0066) despite similar BMI (P = 0.46 and 0.97). In cohort 2, glucose was higher 
in the group with hypertrophy (P = 0.008). After weight loss no statistically significant 
difference in HOMA-IR remained between the groups in the two cohorts.  
Average weight loss in cohort 1 was 7 ± 3 %, and 33 ± 9 % in cohort 2. BMI, waist 
circumference, WHR, fat mass, insulin, glucose and HOMA-IR decreased in all subgroups in 
the two cohorts (P <0.0001 for all values). 
Baseline morphology could predict changes in (Δ) insulin levels and HOMA-IR in both 
cohorts, regardless of whether morphology was studied as a dichotomous variable (P = 
0.0073 and 0.047 for Δ insulin in cohort 1 and 2; and P = 0.013 and 0.0012 for Δ HOMA-IR) 
or continuous variable (P = 0.015, Rho = 0.25 and P = 0.01, Rho = 0.35 for Δ insulin; and  
P = 0.027, Rho = 0.23 and P = 0.0002, Rho = 0.50 for Δ HOMA-IR) as illustrated for cohort 
2 in Figure 8. Adipose morphology could not predict weight loss. Neither baseline BMI, total 
fat mass, WHR nor waist circumference correlated with improved HOMA-IR or insulin. Fat 
cell size alone predicted improved HOMA-IR only in cohort 2 (P = 0.005, Rho = 0.38).  
 
Figure 8. The relationship between adipose morphology and changes in (delta) insulin (a, b) and HOMA-
IR (c, d) in cohort 2. P and Rho values from Mann-Whitney U-test and Spearman correlation test respectively. 
HOMA-IR, homeostasis model assessment of insulin resistance. Figure 2 from study I. 
  31 
4.2 STUDY II 
Forty nine patients were examined before, two and five years after RYGB. 30 patients were 
individually matched for sex, BMI and age with a weight stable control subject at the five 
year follow-up. 
Average BMI was reduced from 43.0 ± 4.8 kg/m
2
 at baseline to 28.8 ± 4.2 kg/m
2
 two years 
postoperatively (P < 0.0001), followed by a slight weight regain to 31.3 kg/m
2 
(P < 0.0001) at 
the five year follow-up. As expected, all clinical parameters improved after two years, 
including average HOMA-IR that decreased from 3.9 to 1.0 (all P < 0.0001). Fat cell volume 
decreased (P < 0.0001) but fat cell number did not change significantly. There was a marked 
decrease in total and regional fat mass and a slight increase between two and five years (all  
P < 0.0001). S-adiponectin increased (P = 0.001) and remained stable at the five year follow-
up. Lipolysis measured as glycerol release decreased two years after surgery and experienced 
an increase up to levels above baseline five years after surgery (both P < 0.0001 when 
normalized per number of cells). Self-reported physical activity increased after RYGB and 
remained stable at the five year follow-up. Between two and five years after RYGB, most 
clinical parameters deteriorated slightly following the weight regain. Fat cell number but not 
volume increased between 2 and five years (P = 0.019 and 0.19). 
In relation to the individually age- and BMI-matched control group, the women examined 
five years after RYGB had lower HOMA-IR (P = 0.002), lower triglycerides (P = 0.02) and 
cholesterol levels (P = 0.003) and higher circulating adiponectin (P = 0.0009) and HDL-
levels (P = 0.02) as seen in Table 5. EVAT was significantly lower than in controls (P = 
0.00006), despite similar WHR and waist circumference.  
Analyses of WAT protein release showed no significant differences between two and five 
years after RYGB for MCP-1 and adiponectin but higher levels for TNF-α (P = 0.003) and 
IL-6 when expressed per ESAT (P = 0.02). In comparison to controls, subjects that had 
undergone RYGB had lower release of TNF-α (P = 0.005 and 0.004) and higher adiponectin 
release when expressed per number of cells (P < 0.0001).  
Serum adiponectin levels and HOMA-IR correlated negatively, both five years after RYGB 
and in the control group. However, in the control group the correlation was steeper and 
HOMA-IR was higher with low adiponectin levels. 
Analyses of distribution of fat cell volume showed normal distributions before RYGB, two 
and five years after as well as in the control group.   
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Table 5. Findings 5 years after gastric bypass in 30 obese women compared with 30 control women pair-
matched for age and BMI  
Measure 5 years after 
RYGB 
Control P-value 
Age, years 49 ± 9 48 ± 9 - 
BMI, kg/m
2
 32 ± 7 32 ± 7 - 
Waist-to-hip ratio 0.93 ± 0.07 0.94 ± 0.06 0.76  (0.86) 
Waist circumference, cm 104 ± 17 106 ±17 0.25 (0.65)  
Hip circumference, cm 111 ± 14 112 ±13 0.23 (0.68) 
Body fat, percentage 44 ± 9 45 ± 10 0.19  (0.66) 
Android fat, kg 35 ± 18 37 ± 18 0.25 (0.58)  
Gynoid fat, kg 7 ± 3 6 ± 2 0.23 (0.62) 
EVAT, kg 1.0 ± 0.7 1.5 ± 0.9 0.00006 (0.02) 
ESAT, kg 2.6 ± 1.4 2.4 ± 1.0 0.21 (0.62) 
S-insulin, mU/l 5.9 ± 2.7 10.6 ± 7.3 0.001 (0.003) 
P-glucose, mmol/l 5.1 ± 0.6 5.1 ± 0.4 0.48 (0.49) 
HOMA-IR, units 1.4 ± 0.7 2.5 ± 1.7 0.002 (0.003) 
P-triglycerides, mmol/l 0.9 ± 0.5 1.2 ± 0.6 0.02 (0.04) 
P-HDL cholesterol, mmol/l 1.63 ± 0.51 1.34 ± 0.36 0.02 (0.001) 
P-total cholesterol, mmol/l 4.2 ± 0.7 4.8 ± 1.0 0.003 (0.003) 
P-glycerol, µmol/l 116 ± 42 108 ± 69 0.59 (0.57) 
P-adiponectin, µg/ml 12.9 ± 5.5 9.1 ± 3.1 0.0009 (0.001) 
Fat cell volume, pl 492 ± 210 711 ± 243 < 0.0001 (0.0008) 
Fat cell number x 10
7
 653 ± 518 366 ±122 0.02 (0.06) 
Glycerol release, µmol/10
7
cells 4.5 ± 1.9 4.7 ±  2.72 0.45 (0.68) 
Glycerol release, mmol/total ESAT 2.4 ±2.0 1.9± 0.8 0.08 (0.20) 
Physical activity, score 2.3 ±0.5 2.1 ±0.7 0.74 (0.21) 
Values are mean ± SD and compared by paired and unpaired (within parenthesis) Students t-test. In some cases, 
n < 30 due to missing values. BMI, body mass index; ESAT, estimated subcutaneous adipose tissue; EVAT, 
estimated visceral adipose tissue; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of 
insulin resistance; RYGB, roux-en-Y gastric bypass. Table 2 from study II. 
 
4.3 STUDY III 
Levels of CCL18 in WAT incubate increased statistically significant over time (Figure 9). 
 Serum CCL18 levels where compared between the 40 most insulin sensitive versus 40 most 
insulin resistant women in a cohort of 220 women with obesity (average HOMA-IR 1.1 and 
5.6 in each group respectively). Serum CCL18 levels were significantly higher in the insulin 
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resistant group (P = 0.0005, Figure 9), in contrast to the serum levels of TNF-α and IL-6 that 
barely differed significantly. 
 
Figure 9. Adipose secreted and circulating CCL18 levels. (A) CCL18 levels from subcutaneous adipose tissue 
incubate collected at baseline and after 1 and 2 hours. n=7 * =  P < 0.05 and ** = P = < 0.001. r.u. = relative 
units. (B) Serum CCL18 levels in insulin sensitive versus insulin resistant obese subjects. *** = P < 0.001. 
Figure 1 from study III. 
Secretion of CCL18 from subcutaneous WAT was correlated to metabolic parameters in two 
cohorts. In cohort 1 (n = 29), linear regression showed a significant relationship between 
CCL18 secretion and BMI (P = 0.0009, r = 0.60), M-value (P < 0.0001, r = -0.75), ATP III 
risk score (P <0.0001, r = 0.81) and triglycerides in plasma (P < 0.0001, r = 0.70). These 
correlations remained significant after adjustment for BMI in multiple regression analyses. 
Independent of BMI, WAT CCL18 secretion correlated with TNF-α and IL-6 secretion (P = 
0.0093 and 0.016). The findings in cohort 1 were validated in cohort 2 (n = 56) where similar 
correlations were observed besides that insulin sensitivity was determined by HOMA-IR 
instead of hyperinsulinemic euglycemic clamp. Circulating CCL18 correlated with 
circulating TNF-α (P = 0.018, Rho = 0.28) but not IL-6.     
To determine the primary cellular source of CCL18 in subcutaneous WAT, CCL18 mRNA 
levels were determined in purified fractions of mature adipocytes, macrophages and 
leukocytes. Results showed that CCL18 was enriched in macrophages (P < 0.001 in 
comparison to leukocytes and adipocytes). In cohort 2, transcription of CCL18 correlated 
with subcutaneous WAT secretion (P < 0.0001, r = 0.68). Gene ontology analyses showed 
that CCL18 expression correlated with expression of genes in the immune system spectrum. 
When correlating CCL18 expression with expression of genes reported to be enriched in M1 
an M2 macrophages respectively, stronger correlations were seen with those in the M2 
spectrum. 
Determination of mRNA levels in M0, M1 and M2 macrophages derived from the human 
THP-1 cell line revealed that CCL18 expression was induced in M2 cells. Recombinant 
CCL18 induced expression of the proinflammatory genes CCL2 and CCL3 in M0 an M2 
cells. There were no effects of recombinant CCL18 on neither adipocyte nor preadipocyte 
lipolysis (assessed as glycerol release), expression of inflammatory genes (TNF-α and IL-6) 
or genes related to extracellular matrix formation (COL1A1, CTSB and COL6A1). Among the 
 34 
genes encoding the previously reported receptors for CCL18, GPER1 expression was higher 
than PITPNM3 in all subtypes, and CCR8 was not detectable. A similar pattern was observed 
in vitro-differentiated adipocytes, where GPER1 expression was higher than in preadipocytes.       
4.4 STUDY IV 
At baseline, 215 women scheduled for RYGB were included. Two years after surgery, 166 
patients were followed-up (77.2 %) and included in further analyses. Omentectomy had been 
performed in 33 patients in addition to RYGB, and these patients were excluded from 
analyses of changes in fat mass and distribution.  
As expected, all clinical and anthropometric parameters improved significantly after weight 
loss (all P < 0.0001). Android-gynoid (AG) and EVAT-total fat mass ratios decreased (both  
P < 0.0001)  
Improved HOMA-IR was predicted by baseline AG-ratio (P = 0.0028, r
2
 = 0.056) and WHR 
(P = 0.0014; r
2
 = 0.063), independent of BMI and age (P = 0.0044 and 0.0023 respectively in 
multiple regression). In multiple regression analyses with BMI and age, AG-ratio and WHR 
remained significant versus changes in HOMA-IR (P = 0.0044 and 0.0023 respectively).   
Weight loss (%) was predicted by DXA measured baseline body fat percentage (P < 0.0001, 
r
2
 = 0.090) and fat percentage in the android region (P = 0.0055, r
2 
= 0.046), and among the 
basic anthropometric measures by BMI (P = 0.0022, r
2 
= 0.056) and body fat percentage 
calculated by formula (P = 0.0083, r
2 
= 0.042). DXA measured fat percentage remained a 
significant predictor in multiple regression with age and BMI (P = 0.0033), as did BMI in 
multiple regression with age (P = 0.0086). Excess BMI lost (%) could not be predicted by 
any DXA measures, but by BMI (P < 0.0001, r
2 
= 0.10), waist circumference (P = 0.0087,  
r
2
 = 0.042) and fat percentage calculated by formula (P < 0.0001, r
2 
= 0.11). BMI remained a 
significant predictor of percentage excess BMI lost after adjusting for age in multiple 
regression (P < 0.0001). 
Finally, comparisons between the predictive properties of DXA measures versus basic 
anthropometric measures were made in multiple regressions analyses. In multiple regression 
with AG-ratio and WHR versus changes in HOMA-IR, none of these predictors remained 
significant. In a multiple regression analysis of DXA measured fat percentage, fat percentage 
calculated by formula and BMI versus weight loss (%), only DXA measured fat percentage 
remained significant (P = 0.0057).      
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Figure 10. Overview summarizing the main findings in this thesis. Study I and IV revolves around prediction, 
illustrated by the Clairvoyant (“Fjärrskådaren”). Study I identified baseline adipose tissue morphology, i.e. 
hypertrophy or hyperplasia, as a predictor of improved insulin sensitivity after weight loss through gastric bypass 
or diet. In study IV, baseline body fat distribution predicted improved insulin sensitivity after gastric bypass, and 
body fat percentage predicted weight loss. In study II, gastric bypass patients were compared to a matched 
control group after weight loss. Results showed that clinical and adipose tissue phenotype was better after gastric 
bypass than in the matched control group. Study III identified CC Chemokine Ligand 18 (CCL18) to be secreted 
from M2 macrophages in adipose tissue. Adipose secreted and circulating CCL18 correlated with metabolic risk 
factors in women.   
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5 DISCUSSION 
5.1 STUDY SPECIFIC ASPECTS 
Study I showed that adipose tissue morphology can predict improved insulin sensitivity after 
moderate weight loss following a diet program, and after pronounced weight loss following 
RYGB. Proper selection of patients for bariatric surgery is of great importance since not all 
patients with obesity can undergo surgery. The fact that current selection criteria still rely on 
BMI despite that BMI has a limited ability to predict metabolic outcome
13, 28
, illustrates the 
lack of proper predictors for metabolic outcome. Adipose morphology adds predictive 
information concerning expected improvement in insulin sensitivity after RYGB, although 
the predictive value is limited in a clinical context. Combining adipose morphology with 
other factors may potentially improve prediction of improved insulin sensitivity after weight 
loss. The importance of weight loss independent mechanisms behind metabolic 
improvements was highlighted by the finding that WAT morphology predicted improved 
insulin sensitivity but not weight loss. 
Study II compared the WAT and metabolic phenotype of patients that had lost weight through 
RYGB with an individually BMI-, age- and sex-matched control group. Interestingly, this 
comparison revealed that after RYGB, patients had reached a “supra-normal” state with 
better insulin sensitivity, lipid profile, higher adiponectin levels and less visceral fat than the 
controls. Adipose secreted TNF-α was lower than in controls and adiponectin higher. Our 
findings suggest that adipose factors including adiponectin levels, adipose hyperplasia and 
body fat distribution may be involved in the metabolic improvement beyond the control state 
after RYGB. Adipose inflammation may be another factor involved in this improvement. 
While adipose release of MCP-1 and IL-6 was unaltered in comparison to controls, TNF-α 
levels where lower. As previously discussed, TNF-α induces insulin resistance in adipose 
tissue, and this decrease after weight loss is likely to be protective. The pattern of IL-6 and 
MCP-1 release may on the other hand potentially reflect a less dynamic and less reversible 
response in expanded fat mass or be less associated with adipocyte size. Furthermore, the 
study confirms the previously demonstrated metabolic improvement after weight loss 
following RYGB, including increased circulating adiponectin, reduced basal lipolysis and 
relative hyperplasia. Between two and five years, weight regain was observed and insulin 
sensitivity decreased slightly and fat cell number but not size increased. The increased fat cell 
number between two and five years after weight loss indicate that adipogenesis has been 
triggered after weight regain, a phenomenon described previously
151
. However, we did not 
find any pool of small fat cells (i.e. bimodal distribution of adipocytes), as have been reported 
by some groups previously
152
. This may be interpreted in the way that newly formed 
adipocytes increase their size relatively fast and that this pool is not identified by size after 
long-term weight regain. These discrepancies may also be attributed to different approaches 
to determine adipocyte size. Although patients were examined after relatively long term, the 
finding of weight regain may indicate that the hyperplastic WAT after weight loss represents 
a “hungry” adipose tissue prone to regain its mass. After weight loss, lipolysis153 and WAT 
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leptin release
103
 has been shown to decrease below the control state which may promote 
weight regain.  
Study III demonstrated that CCL18 is secreted from subcutaneous WAT, primarily from 
macrophages in the M2 spectrum, and affects macrophage expression of inflammatory 
factors. However, no effects could be demonstrated on adipocyte expression of classical 
inflammatory or extracellular matrix genes in vitro. WAT release of CCL18 and circulating 
levels correlated with insulin sensitivity and metabolic disturbances better than the 
established proinflammatory cytokines TNF-α and IL-6. Subcutaneous WAT CCL18 
expression has previously been reported to be upregulated in obesity
154, 155
 and diabetes
156
, 
the latter being in line with our findings on the correlation between CCL18 expression and 
secretion from WAT and between WAT release of CCL18 and insulin sensitivity. Our 
findings indicate that CCL18 may be a novel circulating marker of insulin resistance and 
WAT inflammation, better than the established markers IL-6 and TNF-α. The primary source 
of CCL18 is M2 macrophages, but WAT release of CCL18 was highly correlated to classic 
proinflammatory cytokines as well. This questions the traditional division of macrophages 
into M1 and M2 phenotype, and rather supports more lately notions of intermediate 
macrophage states
157
, including metabolically activated macrophages in obesity
111
. CCL18 is 
known to be involved in development of pulmonary fibrosis
158
, and we hypothesized that 
potential metabolic effects in adipose tissue may be mediated by development of fibrosis, i.e. 
excess extracellular matrix formation from preadipocytes. However, no such effects could be 
demonstrated in vitro although different responses may still potentially be induced in vivo. 
The signaling pathway for CCL18 is not fully elucidated, and our results concerning 
expression of the previously described receptors did not provide any clear pattern supporting 
any of these as the likeliest receptor although GPER1 was most highly expressed.  
Study IV identified body fat percentage as a predictor of weight loss after RYGB and high 
android/gynoid fat accumulation as a predictor of improved insulin sensitivity after weight 
loss. When comparing the predictive value of DXA measures with basic anthropometric 
assessments, body fat percentage measured by DXA performed slightly better than estimated 
by formula or BMI as predictor of weight loss. For prediction of improved insulin sensitivity, 
no significant difference between DXA measured AG-ratio and WHR was observed, 
indicating similar predictive properties of these measures. Predictive values were independent 
of BMI and age. These findings suggest a limited value of DXA examination in addition to 
anthropometric measures to predict metabolic outcome after RYGB. EVAT/total fat mass 
ratio did not predict improved insulin sensitivity after adjustment for multiple testing, 
although this might have been expected given the negative metabolic impact attributed to 
visceral adiposity. This may reflect that, in contrast to AG-ratio, EVAT/total fat mass ratio 
does not take the protective gynoid fat mass
68
 into account to the same extent. Finally, 
favorable redistribution of body fat after RYGB was observed. These results are in line with 
previous findings
141, 159, 160
, and may potentially involve a higher lipid turn-over rate in 
visceral adipose tissue
161
.  
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5.2 GENERAL ASPECTS 
The findings in this thesis highlight the BMI-independent correlation between intrinsic 
factors in adipose tissue and metabolic disturbance before and after weight loss, and put these 
findings in a clinical context.  
As demonstrated in study II, loss of fat mass after weight loss is achieved by decreased 
adipocyte size but not number. Adipocyte size is highly correlated to insulin resistance and 
predicts improved insulin sensitivity after weight loss as seen in study I. We have previously 
shown that reduction in subcutaneous adipocyte size after weight loss correlates with 
improved insulin sensitivity
162
. It may be discussed whether there is a causal relationship 
between adipocyte size and insulin sensitivity, or if they are parallel phenomena with a 
common underlying cause. However, several observations suggest a causal link. According to 
the adipose tissue expandability hypothesis
163
, metabolic disturbances in obesity appears as a 
consequence when adipose tissue reaches a state where it can no longer harbor excess fat. 
Lipids are then instead stored intraabdominal and in muscle, liver, pancreas and other ectopic 
foci where lipotoxicity induces metabolic disturbances. Decreased ability to recruit new 
adipocytes when expanding fat mass will thus result in hypertrophic adipose tissue associated 
with disturbed metabolism. Our observation in study I, that subjects with hypertrophy have 
higher waist circumference and WHR despite similar BMI, may be considered to be in line 
with this hypothesis; approaching the subcutaneous expansion limit early will promote 
visceral and other ectopic fat accumulation. Further notions suggesting a causal link include 
the observation that treatment with thiazolidinediones induce WAT hyperplasia and improves 
insulin sensitivity
164
. In mice, inducing hyperplasia chemically has been reported to improve 
insulin sensitivity
165
. An alternative or additional explanation may be that intrinsic adipocyte 
factors are of importance for the development of insulin resistance. Large adipocytes are 
reported to have higher lipolysis rate
84, 92
, and more proinflammatory adipokines such as 
MCP-1 and IL-6 are released from larger adipocytes
166
. These factors contribute to insulin 
resistance. 
What may explain the identified predictive properties of adipose morphology and body fat 
distribution? One potential explanation of the findings could be that most WAT changes in 
the group studied herein are reversible after weight loss. If deteriorated WAT phenotype is a 
major contributor to metabolic disturbance and normalization (or supra-normalization) of 
WAT phenotype occurs after weight loss, then normalization of metabolic phenotype would 
be expected after weight loss. Inversely, if WAT phenotype in the obese state is “benign” and 
metabolic disturbance still occurs this may indicate other causes outside of WAT, potentially 
less reversible after weight loss. As discussed in the background, preserved beta cell function 
seems central to enable reversal of disturbed glucose metabolism after weight loss. The high 
degree of normalization of insulin sensitivity after weight loss in our cohorts may potentially 
be attributed to preserved beta cell function (only a minority had T2D, and patients with 
insulin treatment were excluded), although this was not studied specifically herein. With a 
high degree of reversibility after weight loss, worse metabolic status before weight loss will 
be associated with larger improvement after weight loss. Thus, factors closely related to 
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metabolic disturbances will likely be predictors of improved metabolic outcome after weight 
loss in this group which may also explain our findings. However, the results herein shows 
that several factors considered to associate with metabolic disturbance (including BMI) do 
not display these properties, whereas intrinsic adipose factors including fat cell size in fact do, 
and thus seem more associated with insulin sensitivity and the potential to reverse insulin 
resistance after weight loss.    
When comparing our results in study I with other studies we found some conflicting results 
concerning adipocyte size and metabolic improvement. Another study
46
 showed a decreased 
resolution of T2D with increasing fat cell size, whereas we observed a higher degree of 
improved insulin sensitivity with increasing fat cell size. If a cohort of patients with diabetes 
is selected; adipocyte hypertrophy may reflect a more advanced disease stage and a higher 
probability of irreversible beta cell failure, and thus decreased chance of T2D remission. In 
our cohorts, including primarily patients with insulin resistance but not T2D, the reversibility 
of insulin resistance is still high. Displaying the phenotype associated with insulin resistance 
in this cohort will thus be associated with the highest potential for improved insulin 
sensitivity. Analogously, this “switch” from positive to negative predictors when studying 
subjects with insulin resistance but without T2D in comparison to patients with T2D may also 
be applicable for the findings in study IV, since a negative relation between visceral obesity 
and diabetes remission has been reported
167
. Differences between patients with and without  
T2D have been reported previously in the association between adipocyte size and insulin 
sensitivity
102
. To summarize, the seemingly conflicting findings described above may not be 
conflicting but only reflecting different relations between predictors and improved insulin 
sensitivity or diabetes status depending on whether the patients display impaired insulin 
sensitivity alone or have progressed into T2D. Our studies highlight this phenomenon and 
add information on predictors for improved insulin sensitivity after weight loss in patients 
without T2D.      
Many previous studies on improvements in glucose metabolism after bariatric surgery have 
focused on T2D remission. In the ongoing debate concerning indications for bariatric 
surgery
30, 168
, focus is shifting from weight loss to the positive metabolic effects of surgery. 
Since the degree of T2D remission is reduced in more advanced T2D stages
43, 44
 it may be 
argued that interventions should be initiated earlier to reverse metabolic disturbances with 
sustained efficacy. Patients like the majority included in this study; with obesity and insulin 
resistance but without established T2D, may thus be considered particularly suitable for 
bariatric surgery in terms of reversibility of metabolic disturbances and prevention of future 
comorbidity. Previous studies on the elevated T2D incidence in patients with hypertrophic 
adipose tissue
81, 82
 highlight the elevated risk of metabolic disease in this specific group, 
which may strengthen the indication for preventive interventions.   
In a clinical context, the value of the predictors identified in study I and IV is limited although 
they may give an indication on average expected weight loss or improvement of insulin 
sensitivity despite large inter-individual differences. The reason for the weak correlations 
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between the predictors and outcome probably reflect the fact that the mechanisms behind 
improved insulin sensitivity and weight loss after RYGB (and diet interventions) are highly 
complex, involving many factors with a large inter-individual variation including eating 
behavior, physical activity, genetic predisposition, hormonal factors and nicotine use etcetera. 
To identify one factor summarizing all these aspects would probably be difficult and weak 
associations are likely to be expected for many single predictors. Using a combination of 
independent predictors could potentially improve the predictive precision. Preoperative BMI 
is included in many predictive models of T2D remission after bariatric surgery. We did not 
find BMI to predict improved insulin sensitivity, but WHR did. Could replacing BMI with 
WHR in these models sharpen the predictive accuracy? 
5.3 STRENGTHS AND LIMITATIONS 
One major general strength of the cohorts in this thesis include the extensive translational 
characterization of the human study participants; ranging from clinical parameters through 
anthropometric measures to studies of adipose tissue structure and function, and adipocyte 
gene expression and protein secretion. Another strength is the longitudinal approach with a 
long follow-up time after weight loss, in the weight stable phase after two years and after 
some weight regain.  
The detailed characterization is expensive as well as time and labor consuming which limits 
the number of patients included in the cohorts, although still relatively large when taking the 
extensive characterization into account. The number of patients does however limit the ability 
to perform subgroup analyses and extensively correct for possible confounding with 
sustained precision and power. Potential confounders that have not been taken into account 
may include physical activity, diet and nicotine use. Physical activity affects insulin 
sensitivity and has been reported to induce a more pronounced loss of visceral mass than 
hypocaloric diets
19
. Altered food preferences have been reported after RYGB
169
, which may  
potentially influence metabolic status independent of weight loss. As reviewed
170
, nicotine 
has been linked to visceral fat accumulation, increased adipocyte differentiation, increased 
lipolysis and weight loss. Thus, these factors may potentially influence some of the exposures 
and outcomes in the studies herein and thereby act as confounders. Although self-reported 
physical activity did not differ significantly between groups in study II, self-reported physical 
activity may suffer from limited validity. 
Many organs besides WAT, including skeletal muscle, liver and pancreas as described, 
contribute to the development of metabolic disturbances in obesity and the subsequent 
reversal after weight loss. The relative contribution of adipose factors to whole-body effects 
is hard to quantify and some effects observed may admittedly not primarily be associated 
with WAT factors. Furthermore, the primary model for weight loss in our studies is RYGB. 
RYGB induces other alterations than weight loss that may affects metabolism
39
, including 
hormonal changes. For example, the early diabetes remission before substantial weight loss 
has to a large extent been attributed to incretin effects
40-42
. Thus, other mechanisms 
independent of weight loss or WAT phenotype may contribute the positive effects on 
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metabolism observed, including the supranormality after RYGB in study II. These factors are 
not studied in this thesis. 
Some patients were lost to follow-up in the longitudinal studies, which may potentially have 
influenced the results by introducing selection bias. For example, 22.8 % were lost to follow-
up in study IV. Patients that are lost to follow-up may differ in their outcome from those 
followed up. It might be that those with worse outcome are less prone to reappear at the 
follow-up examinations. However, the only baseline characteristics differing between those 
followed-up and not in study IV were slightly higher weight. Another source of selection bias 
may be at the point of inclusion, were some patients may be considered less suitable to 
participate for some reason not reflected by the exclusion criteria.     
The generalizability of our findings deserves discussion. The studies herein are all based on 
abdominal subcutaneous WAT and no other subcutaneous or visceral depots. Depot-specific 
differences in adipocyte size
171
 and lipolysis
75
 are known to exist, and the findings are 
probably not directly generalizable from one depot to another. In the case of CCL18, the 
expression in patients with insulin resistance is reported to be doubled in visceral WAT
172
. 
Furthermore, the study participants in our studies are primarily women, reflecting a consistent 
difficulty in recruiting enough men in this kind of studies since the majority of patients that 
undergo bariatric surgery are women
31
. The generalizability of the findings to men is not 
known. Body fat distribution differs between men and women, and change into a more 
android pattern after menopause in women accompanied by increased risk of metabolic 
disturbance
69, 173
. Menopause constitutes another factor that has not been taken into account 
which may have influenced the results. Another factor that has not been considered and that 
may limit the generalizability is ethnicity. The majority of patients included are of Swedish 
origin and ethnic specific differences in for example body fat distribution are known to 
exist
174
. Moreover, the great majority of the included patients do not have T2D and none are 
on insulin therapy. Correlations found herein may look different in patients with T2D as 
discussed above.   
Strengths in study I and III include that the findings are validated in several cohorts. Our 
findings concerning supra-normality metabolic and WAT findings after RYGB have been 
validated in an additional study including a matched control group. In this study, patients 
were matched two years after RYGB and insulin sensitivity was also measured by clamp
175
. 
This study confirmed higher HOMA-IR and more hyperplastic adipose tissue in the post–
obese state, although clamp values did not differ significantly between groups. A limitation of 
the findings in study IV is the lack of a validation cohort.  
When interpreting the results in the studies herein, it should be taken into account that the 
results are sometimes secondary analyses of data with a different pre-specified primary 
outcome (for example metabolic effects of omentectomy and effects on adipose tissue of 
different diets in study I).  
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5.4 ETHICAL ASPECTS 
All four studies in this thesis include human participants, and the ethical considerations are of 
greatest importance. All studies were performed in agreement with the principles of the 
Declaration of Helsinki and approved by the regional ethics committee in Stockholm. 
Informed written consent was received from all participants before examinations, and patients 
were free to withdraw their participation without further explanation throughout the 
examinations. 
The examinations include subcutaneous adipose tissue biopsies. Although performed under 
local anesthesia, minor discomfort or pain may be experienced. A hematoma is expected after 
the biopsy, and sometimes a minor scar remains. It may be argued that this would interfere 
with the “do no harm” principle, but could be considered acceptable weighing in the benefits 
of the study including increased knowledge of the mechanisms behind the metabolic 
syndrome. All examinations are voluntary to the participants and no serious complications 
have been experienced during the more than 2000 biopsies performed at our research center 
to date. Besides, the principle of autonomy is always respected since patients are free to 
discontinue their participation whenever they wish.  
Exposing healthy volunteers to radiation may be ethically complicated. However, the DXA 
examinations in our projects only confer a minor dose of radiation, equal to the background 
radiation of one day in the Stockholm area which is considered harmless within healthcare. A 
special permit from the Authority for Radiation Protection was achieved before the DXA 
examinations took place. 
Analyzing blood samples and performing examinations concerning health status infers a risk 
or opportunity that previous unknown disease or risk factors for future disease are discovered, 
such as diabetes or hypertension. Patients are informed in advance that participation includes 
extensive health controls. All results are analyzed by medical doctors, and when necessary 
patients are referred to suitable health care instance to ensure adequate follow-up.  
Handling of personal data and tissue samples demand ethical considerations not to interfere 
with the integrity of the patients. In our study, data from the examinations are coded and the 
key kept locked in. Only decoded material was then analyzed. Blood and tissue samples are 
also decoded in the handling and cannot be associated with a specific participant. Patients 
have given their written consent to the data handling.  
Taken together, the ethical aspects discussed above are considered to be handled in a 
reasonable way in our studies and the risk-benefit balance acceptable. 
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6 CONCLUSIONS 
Study I. Adipose tissue morphology predicts improved insulin sensitivity following moderate 
or pronounced weight loss, although the clinical implication may be limited. In patients 
without T2DM, adipose tissue hypertrophy correlates with larger improvement in insulin 
sensitivity after weight loss.   
Study II. Weight loss through RYGB improves several metabolic and adipose tissue 
characteristics beyond the control state in women, despite weight regain. These include 
improved insulin sensitivity, better lipid profile, higher circulating and adipose secreted 
adiponectin levels, more and smaller fat cells (i.e. hyperplasia) and less visceral adipose 
tissue.  
Study III. CCL18 is released from adipose tissue in a time-dependent manner. The primary 
source of CCL18 in adipose tissue is macrophages in the M2 spectrum. Adipose secreted and 
serum levels of CCL18 correlate positively with metabolic parameters in women. In vitro, 
recombinant CCL18 does not affect adipocyte expression of inflammatory proteins or 
extracellular matrix components, but increases expression of inflammatory proteins in 
macrophages. CCL18 may constitute a novel marker of metabolic disturbance and WAT 
inflammation in obesity. 
Study IV. Independent of BMI and age, DXA measured AG-ratio and WHR predict 
improved insulin sensitivity after RYGB and BMI and body fat percentage measured by 
DXA or estimated by formula predicts weight loss after RYGB. However, DXA 
measurement of body fat mass and distribution has a limited clinical value for prediction of 
metabolic outcome or weight loss after RYGB in women since the precision is low and DXA 
do not perform much better than basic anthropometric measures. Body fat distribution is 
altered in a metabolically favorable manner after weight loss. 
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7 FUTURE PERSPECTIVES 
Several questions concerning prediction of metabolic outcome after RYGB remains. What 
are the best predictors of outcome? Can the predictors identified herein improve existing 
predictive models or be useful in models including other factors as well? Can long-term (5 or 
10 years or more) metabolic outcome be predicted by adipose parameters at baseline or two 
years after surgery?  
There is limited knowledge about BMI-independent predictors of long-term mortality after 
RYGB. Can long-term incident cardiovascular disease or mortality after RYGB be predicted 
by WAT characteristics?  
Further validation of the findings herein would be interesting in other populations including 
men, in particular in study IV where a validation cohort is lacking. 
BMI is still widely used in the follow-up of patients after bariatric surgery, despite its 
limitations as a tool for cardiovascular risk stratification. What characterize patients with a 
BMI within the non-obese range but with a high body fat percentage after RYGB? 
In study II, it was shown that patients displayed a more hyperplastic adipose tissue after 
RYGB. What are the long-term consequences of these changes? Is it really protective or does 
it leave patients with a “hungry” adipose tissue prone to weight regain? The longitudinal 
follow-up of the cohorts including RYGB patients continues, enabling future long-term 
follow-up. Does T2D incidence differ between the weight loss group and the matched 
controls? 
Patients usually regain weight after initial weight loss after RYGB. What characterizes 
patients with a high degree of weight regain? Can they be identified early or do their adipose 
tissue display certain characteristics? Does weight regain and spontaneous weight gain follow 
the same pattern in adipose tissue? 
Can CCL18 predict metabolic outcome after weight loss? Validation of the correlation 
between CCL18 and insulin resistance in other cohorts would be of interest.   
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